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INTRODUCTION 
 Diabetes Mellitus [DM] is probably one of the oldest diseases 
known to man. It was first reported in Egyptian manuscript about 3000 
years ago1. It is the most prevalent endocrine and metabolic disease 
which affects human beings. The disturbance of carbohydrate, protein 
and fat metabolism cause a defect in insulin secretion which can lead to 
chronic hyperglycemia causing diabetes mellitus.2 
Epidemiological studies 
According to the International Diabetes Federation (2010), at least 
285 million people in the world have been affected by diabetes and the 
number might escalate to 438 million by the year 2030. Out of this two 
thirds will be from the low to middle income countries.3 
India, the second most densely populated country in the world has 
been severely affected by the global diabetes epidemic. As per the 
International Diabetes Federation (2013), approximately 50% of all 
people with diabetes live in just three countries: China (98.4 million), 
India (65.1 million), USA (24.4 million).4 
By the end of 2025 ,75 % of the people in the developing countries 
will be diabetic. Avery high  percentage of this will be from 
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India.(5)Diabetes  is one of the major causes of concern in India as a very 
large number of  people are affected by diabetes and the number is 
increasing every year.It may trigger upto 57.2 million by 2025 and by 
2030 nearly 80.9 million Indians will be affected with diabetes6 
The risk factors associated with diabetes are stress, insulin 
resistance, and increased body mass index, family history of diabetes, 
physical inactivity and sedentary life style habits. 
Diabetes mellitus is classified generally into 2 types 
Type 1 diabetes mellitus which is also known as Insulin Dependent 
Diabetes Mellitus [IDDM] is due to defects in insulin secretion. It is an 
auto immune disease which causes destruction of the insulin secreting 
beta cells in the pancreatic islets. 
Type 2 diabetes mellitus which is also called Non Insulin 
Dependent Diabetes Mellitus [NIIDM] is caused by reduced sensitivity of 
tissues to the metabolic effects of insulin. This is called as insulin 
resistance.7 
Type 2 diabetes mellitus (Type 2 DM) shows strong familial 
aggregation. Increase in age, obesity, and physical inactivity are high risk 
factors which result in type 2 diabetes. Nearly 55% of type 2 diabetes 
mellitus is caused by obesity. During the 1960's and 2000's there has been 
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an increase in childhood obesity which has resulted in this type of 
diabetes mellitus in children and adolescents.8 
Type 2 diabetes mellitus and coronary heart diseases are the most 
widely spread non communicable diseases in the developing countries. 
The spread of Diabetes mellitus has increased in past 30 years in India 
due to lack of awareness and illiteracy.9 Type 2 diabetes mellitus is found 
to be most prevalent in families with high degree of genetic involvement. 
Insulin resistance because of reduced glucose utilization in skeletal 
muscle is found to be present in many non diabetic first degree relatives 
of type 2 diabetes mellitus patients. It is associated with increased 
frequency of human leucocyte antigen alleles. The HLA types DR3 and 
DR4 are most commonly associated with diabetes mellitus. Identical 
twins are more prone to develop diabetes than others. The risk is around 
70-90 percent.10 
 Risk of developing diabetes is greater in a person if one of the 
parents have type 2 diabetes mellitus. The risk increases up to 40%, if 
both parents have type 2 diabetes mellitus.10 
The pathophysiology of type 2 diabetes mellitus is characterized by 
impaired insulin secretion, insulin resistance and excessive hepatic 
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glucose production, Obesity-visceral or central is particularly common in 
type 2 diabetes mellitus. 
Obesity leads to insulin resistance. Circulating levels of insulin 
may be normal or increased in such people, yet it is inadequate to control 
blood glucose levels due to insulin resistance.  Their glycemic status can 
be brought to control by weight reduction and antiglycemic drugs, as 
insulin resistance can be improved with weight reduction11. A diabetic 
patient may have symptoms like visual blurring, polydipsia, polyuria and 
polyphagia. The patient may also have marked weight loss in severe 
uncontrolled diabetes. If left uncontrolled, the patient may go in for 
diabetic ketoacidosis. Negligent attitude, irregular improper drug intake 
by the patient or non effective treatment might ultimately result in 
diabetic coma and death. 
Insulin Resistance 
Insulin resistance is due to:- 
• Inability of muscle and fat to respond to insulin when there is 
increase in glucose and when the liver is unable to respond because 
of decreased glucose output. 
• Inability of the beta cell to compensate insulin resistance by 
secreting additional insulin. 9 
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People are affected by type 2 diabetes mellitus as a consequence of 
over eating when combined with obesity and under-activity. Risk of 
developing type 2 diabetes mellitus increases 10 fold in people with body 
mass index of more than 30 Kg/m2. These diabetics have genetically 
impaired beta cell function, lessoned beta cell mass or susceptibility of 
beta cell being attacked by toxic substances like free fatty acids or 
inflammatory cytokines. 10 
Criteria for Diagnosis of Type 2 Diabetes Mellitus: 
• Fasting plasma glucose greater than 126 mg/dl or symptoms of 
diabetes. 
• Random blood glucose greater than 200 mg/dl  
•
  HbA1c greater than 6.5 percent or post prandial plasma glucose 
greater than 200 mg /dl during glucose tolerance test. 10 
Heart Rate Variability (HRV)  
Heart rate variability measures the time taken between hear beats 
and is an effective tool in assessing the autonomic function of the heart. 
HRV is also known as RR variability.12 
HRV analysis is a non invasive method of assessing cardiac 
activity and autonomic nervous system status which is responsible for 
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regulating cardiac activity. HRV is most effective in monitoring the 
autonomic nervous system (ANS).13 In order to maintain homeostasis of 
the cardiovascular system, interactions between the sympathetic and 
parasympathetic nervous system becomes integral.14 The balancing action 
of the sympathetic nervous system and parasympathetic nervous system 
plays a pivotal role in controlling heart rate. Sympathetic over activity 
increases heart rate and reduces cyclical beat to beat variation, on the 
other hand parasympathetic over activity decreases heart rate and 
increases beat to beat variation. 13 
Heart rate fluctuations around the mean heart rate reflects the status 
of cardiorespiratory control system. HRV is an important tool for 
monitoring post infarction condition of diabetic patients.13 
HRV is a tool for measuring neurocardiac functions that reflects 
interactions between the heart and the brain and the autonomic nervous 
system.13 
The Role of HRV in Diabetes Mellitus 
Uncontrolled diabetes can result in severe autonomic dysfunction 
of vital organs and may even lead to sudden death. Diabetic patients have 
higher risk of death after acute myocardial infarction than non –diabetic 
patients.15 
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 HRV can measure the autonomic activities through low frequency, 
an index of sympathetic modulation and of high frequency, an index of 
parasympathetic modulation. 
 HRV analysis helps to evaluate the autonomic cardiac activity in 
various pathophysiologic conditions. Any impairment in heart rate 
variation is considered to be a marker of autonomic neuropathy in 
diabetic subjects.16 
Heart rate variability serves as a marker for the autonomic control 
on cardiac electrophysiological properties. It also provides information 
for accurately determining risk factors.16 
 HRV analysis is non- invasive, risk free, easy to perform and has 
become an effective and vital tool which provides prognostic information 
to detect heart diseases. 
 A healthy heart is not static and changes dynamically with respect 
to physiological functions. If variability of RR interval is high then the 
functioning of heart is good. The mortality related to cardiac disorders 
may rise due to increased sympathetic over activity and parasympathetic 
hypo activity. 17 
 Visceral fat has its action on liver which could result in increase in 
gluconeogenesis and its effect on muscle which could impair glucose 
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uptake and its utilization. Cytokines constituting the tumour necrosis 
factor and hormones consisting of leptin are secreted from adipose tissue 
and could result in interference with insulin action. Through increased 
physical activity and dietary restraint the development of type 2 diabetes 
mellitus can be prevented.18 
Complications of Diabetes Mellitus 
 The diabetes mellitus complications can be grouped into the micro 
vascular and macrovascular complications. Long term complications of 
diabetes may lead to retinopathy which may result in loss of vision, 
nephropathy which may result in renal failure and peripheral neuropathy 
which might result in foot ulcers and amputation.19 
Diabetic Neuropathy 
Nerve dysfunction as a consequence of diabetes mellitus is known 
as diabetic neuropathy. This is due to neurovascular injury which 
involves small blood vessels that supply nerve fibres. 
Diabetic Retinopathy 
Diabetes mellitus is an important cause of preventable blindness in  
both the developing and the  developed countries. Patients with diabetic 
retinopathy are  more likely to become blind than non-diabetics. 
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Diabetic Nephropathy 
 Diabetic nephropathy is the most important cause of chronic 
kidney disease and End stage renal failure which is a microvascular 
complication of diabetes. 
Macrovascular Complications of Diabetes Mellitus: 
 The macrovascular complications of diabetes mellitus are: 
• Coronary heart disease 
• Peripheral vascular disease 
• Stroke  20 
 In patients having type 2 diabetes mellitus, there is a strong 
1.5 to 3 fold rise in the ischemic heart disease mortality.21 Compared 
with normal population, 75 to 90 percent of coronary artery disease 
patients are prone to have diabetes and it can increase the effects of 
other cardio vascular risk factors.22 
 The commonest cause for mortality in type 1 diabetes mellitus and 
type 2 diabetes mellitus are diseases like myocardial infarction and stroke 
which can lead to death.22 
Haemodynamic and Metabolic Factors  
 The factors which are required for the development and 
progression of complications which are neurovascular in origin in 
diabetes mellitus are metabolic factors and hemodynamic factors. 
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 The factors regulating hemodynamic function are Rennin 
Angiotensin System (RAS) which could have major role in diabetes 
associated atherosclerosis. The endothelial (ET) and urotensin system are 
regulated by vasoactive hormone system which could play a major role in 
complications which are of macrovascular in nature in diabetes mellitus. 
New factors like complement system and tumour necrosis factor related 
apoptosis inducing ligand (TRAIL) has a major role in macrovascular 
complications.23  
Other Complications of Diabetes Mellitus 
Poorly controlled diabetes mellitus can result in diabetic 
ketoacidosis which is one of the many complications of diabetes mellitus. 
It is also characterised by disturbances in the cognition which is one of 
the chief symptomatology in neurology. Extreme serum osmalarity and 
glucose is seen in conditions like non – ketotic hyperosmolar coma. This 
can cause cellular dehydration without ketoacidosis. When excessive 
insulin is administered, it results in insulin shock with loss of 
consciousness and hypoglycaemia which can lead to death.24 
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AIM AND OBJECTIVES 
PRIMARY OBJECTIVE: 
• The aim of the study is analyse the Heart Rate Variability in 60 
offsprings of type 2 diabetes mellitus. 
• To analyse HRV in 30 offsprings of type 2 diabetes mellitus, 
who are not diabetics [control group]. 
• This HRV analysis is compared with 30 offsprings of type 2 
diabetes mellitus, who are diabetics [study group]  
SECONDARY OBJECTIVE : 
• Comparison of HRV with other parameters like lipid profile, blood 
glucose, glycosylated haemoglobin, B.M.I between study and 
control groups. 
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REVIEW OF LITERATURE 
As a consequence of increased globalization and urbanization there 
is a massive increase in the epidemic of T2DM. International Diabetes 
Federation (IDF) 2013 has stated, 85% to 95% of all diabetics are T2DM 
in high income nations and the percentage is further high in low and 
middle income nations.25 
According to a survey taken in 2004 by Wild et al. the number of 
people affected by diabetes is 31.7 millions and the expected rise in 2030 
is 79.4 millions.26 
Shabana Tharkar et al. assessed the pattern of diabetic cases in 
India. Their research was focused on how far the research on diabetes 
was implemented in clinical practice in India. Their conclusion was that 
there was a wide gap between translation of research findings and 
recommendations and their implementation during practice at all levels of 
health care in India. 27 
Autonomic Nervous System 
  The most important part in homeostasis is played by autonomic 
nervous system. It is only through this system that the unconscious neural 
control mechanisms operating in the body is affected. This system has the 
capacity to innervate the cardiovascular, respiratory system, smooth 
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muscle of the GI tracts and glands throughout the body. The autonomic 
nervous system can be controlled through centrally diffused modulating 
systems like brain stem, limbic system and frontal lobes which regulate 
the arousal and background behavioural responses to threat. The output of 
the autonomic nervous system is divided into two divisions, the 
sympathetic and parasympathetic system. 28 
A great number of visceral organs are innervated by both 
sympathetic and parasympathetic nerve fibres. The sympathetic and 
parasympathetic nerve fibres always exert opposite effects in a particular 
organ, this ongoing activity is referred to as sympathetic tone or 
parasympathetic tone or tonic activity. The activity of one division can 
dominate the activity of the other under any given circumstance. There 
will be sympathetic dominance for a particular organ when the 
sympathetic fibre’s amount of firing to that organ increases above the 
toxic level, and when this is coupled with a simultaneous decrease in the 
parasympathetic fibre’s frequency of action potential to the same organ. 
The reverse circumstances can also hold good for the parasympathetic 
dominance when there is massive wide spread discharge taking place 
more frequently in the parasympathetic system than in the sympathetic 
system.29 
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Both the divisions are reciprocally controlled by the autonomic 
nervous system which acts as a regulator of visceral activities usually 
outside the realm of consciousness and voluntary control in activities like 
circulation, digestion, sweating and pupillary size. However it cannot be 
entirely said that an individual does not have control over the activities of 
autonomic nervous system  (ANS).29 
Hypothalamus and Autonomic Nervous System (ANS) 
 The hypothalamus can integrate the information sent from brain 
and the body. It is only through this activity the individual adapts to the 
environment and the species. Consequently other functions are regulated 
by neuroendocrine and autonomic hypothalamic process along with 
appropriate behaviour that is mediated by neuronal influences on the 
other areas of brain. There are various hypothalamic systems that have 
control over metabolism, circulation and the immune system. 
 As these systems are very important for survival, their function 
could be highly dependent on one another’s performance and they often 
have similar hypothalamic structures. The system's function which could 
be influenced by various factors such as time of the day, stress, sensory, 
autonomic feedback and by various hormones circulating in the 
circulation. These systems can interact by the influence of 
suprachiasmatic nucleus (the biological clock), which could impose its 
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rhythm over the body by communicating through three different routes of 
communication  
• By the secretion of hormones  
• By the parasympathetic effect 
• By the sympathetic autonomic nerves control  
Thus hypothalamus which is present in the brain stem plays an 
integral role in coordinating autonomic, somatic, endocrine, emotional 
response and other states of behaviour. Different stimuli could result in 
changes in their responses of autonomic activity in the body, which can 
be influenced by the prefrontal association cortex by its involvement of 
emotional expression characteristic of an individual. Persistent chronic 
alterations in a state of mental stress or transitory physiological 
alterations under the sympathetic and parasympathetic limb activities can 
create imbalance between the limbs resulting in pathophysiological 
variants of various diseases.30 
The activation of sympathetic system can result in flight or fight 
response which could result in increase in heart rate, constriction of blood 
vessels and increase in blood pressure. The slowing of heart rate due to 
parasympathetic activity can stimulate vasodilation of blood vessels 
resulting in decreasing the force of heart contraction. 
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Heart Rate Variability (HRV) and Respiratory Sinus Arrhythmia 
(RSA) 
 The assessment of HRV has been widely practised in various 
diverse group of disciplines. During inspiration the heart rate increases 
and during expiration it decreases. Contribution of RSA to HRV can be 
measured as the high frequency (HF) components of variation in 
consecutive RR intervals or ECG31.The measurements of vagal nerve 
trafficcant cannot be measured directly. Stephen Hales and Von Haller 
first observed the rhythmic variation of heart rate.32 The application of 
HRV is used in different fields in medicine and surgery. 
The significance of vagal cardiac innervation which regulate the 
heart rate variability was first recognised by Wheeler and Watkans. The 
reduction or loss of beat to beat HRV in diabetics was observed and 
recorded by them.33 
Physiologic Aspects of HRV 
 Heart rate variability is due to variation in cardiac activity at rest 
during the respiratory cycle (respiratory sinus arrhythmia). The other 
factors like exercise, environmental factors and circadian rhythm could 
also contribute towards it. The beat to beat variations occurring in entire 
cardiac cycle length is commonly referred by the term heart rate 
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variability (HRV). The synonyms used for HRV are RR Interval 
tachogram and RR variability.  
Classification  of Heart Rate Variability 
 They are classified as : 
• Time domain measures  
• Frequency domain measures 
The time domain measures is used for assessment of overall 
magnitude of HRV. This domain does not help in appreciating finer 
aspects of variation in heart beats but this domain can be easily assessed. 
The assessment of spectral power analysis helps in finding the 
instantaneous heart rate variation. Frequency domain measures is used for 
achieving a more precise assessment of autonomic function in both the 
experimental and clinical settings.  The five minute lead II ECG helps in 
plotting RR tachogram to its frequency spectrum. It can be done using 
fast fourier transformation or auto regressive modelling. The entire 
frequency spectrum is 0 to 0.4 Hz .31 
Classification of Power Spectrum Analysis 
 The power spectral analysis of heart rate variability can be 
classified based on three spectral components. 
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• High frequency band width measuring 0.15 to 0.4 Hz 
• A low frequency band width measuring 0.04 to 0.15Hz 
• A very low frequency band width measuring 0 to 0.04Hz34 
HRV in other Studies 
 The fact that autonomic nervous system influences the heart rate 
has been quoted in the European Heart Journal, task force of the 
European society of Cardiology guidelines. The autonomic nervous 
system controls the heart rate and rhythm although the cardiac auto 
rhythmicity could be intrinsic to various pace maker tissues35. 
 Noma A, Trautwein W et al did research study on rabbits sinoatrial 
node and found out that vagus nerve innervating it, release acetyl choline 
which results in potassium efflux causing hyperpolarization. Acetyl 
choline inhibits the hyperpolarization activated pacemaker current. 36 
 Chess GF, Tam RMK reported in their research study that 
parasympathetic nerve innervating the SA node is dominant, the acetyl 
choline released from the vagal nerve endings decrease the release of 
norepinephrine from the sympathetic nerves. So a balance of 
parasympathetic and sympathetic activity is maintained.37 
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 Levy MN had showed in his work that interactions between 
parasympathetic and sympathetic systems proved that there could be 
vagal tone during resting condition. 38 
 Akselrod et al have stated in their paper that the variation in the 
RRinterval at resting condition indicates that there is finetuning in the 
mechanism that controls variations in heartbeat.39 
Schwartz PJ, et al had found out in their study on cats that 
excitation always evoked a clear reduction in the discharge of cardial 
vagal units and a clear increase in the discharge of cardiac sympathetic 
fibres .40 
Ahsan H Khandoker et al in their study on T2DM with 
complications like, nephropathy, peripheral nephropathy and retinopathy 
and found out the autonomic imbalance was more depending on type and 
severity of complications due to diabetes. They also emphasized how the 
treatment has to be improved  and advanced based on the complications.41 
Vadim .V. Klimonto V et al conducted a study on sixty seven 
women with type 2 diabetes, out of which 46 patients had cardiovascular 
autonomic neuropathy who underwent simultaneous continuous glucose 
monitoring and Holter recording. They recorded eight glucose variability 
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indices and found out fasting state is preferable for HRV estimation when 
compared to postprandial state. 42 
Ana Leonov Rivera et al conducted a study on 75 subjects who 
were recently diagnosed to have diabetes and 75 long standing diabetic 
patients. In this study they recorded the HRV and blood pressure in 
different positions-supine, standing and controlled breathing test and 
found out the reduction of HRV in diabetic patients, who had a increased 
risk of mortality. 43 
S.K.M. Azizul Islam et al in their study on “Association  between 
diabetic peripheral neuropathy and heart rate variability in subjects with 
type 2 diabetes”, revealed, that parasympathetic activity was reduced with 
increased diabetic peripheral neuropathy severity in male individual, 
suggesting foot examination would be helpful in identifying patients at 
risk of cardiac autonomic neuropathy. 44 
Claudio de Angelis et al in their study “Modified Autonomic 
Balance in offsprings of Diabetes detected by Spectral Analysis of Heart 
Rate Variability” found an alteration in activity in healthy offsprings of 
non-insulin dependant diabetes mellitus (NIDDM) patients with an 
increased sympathetic tone and a decreased parasympathetic tone. This 
finding was clinically preceding glucose intolerance and they stressed 
family history of NIDDM should be taken into consideration whenever   
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measures of power such as spectral analysis of HRV is performed in 
normal subjects.45 
Stuckey MI and Petrella R.J in their study on “Heart Rate 
Variability in Type 2 Diabetes Mellitus.” considered exercise as an 
important component to T2D prevention and treatment strategies. The 
most pronounced changes in HRV were realized following the exercise 
intervention with the greatest frequency of supervised session and with 
the greatest intensity and duration of exercise bouts. These findings 
suggest that exercise following current American College of Sports 
Medicine/ American Diabetes Association guidelines may be important in 
the prevention and treatment of T2DM to improve autonomic function 
and reduce the risk of complication and mortality.46 
Stavroula Kalopita et al in their study on “Relationship between 
autonomic nervous system function and continuous interstitial glucose 
measurement in patients with type 2 diabetes” examined whether there 
was relationship between autonomic nervous system function and 
glycaemic variability (GV) in patients with type 2 diabetes mellitus.  In 
this study it was shown for the first time that GV calculated during a 24 
hours continuous glucose monitoring system and ECG Holter monitoring  
system indicating autonomic dysfunction was present in T2DM even in 
the initial stage of diabetes.47 
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Jaakko Tuomilehto et al in their study on subjects with impaired 
glucose tolerance showed how to prevent T2DM by life style 
modification. The research study was conducted among 522 middle aged 
over weight subjects (men & women) revealing improvement of glucose 
tolerance and reduction in the magnitude of cardiovascular risk factors 
thereby preventing or postponing the onset of T2DM. 48 
A Fiorentini et al in their study on “Circadian rhythm of autonomic 
activity in nondiabetic offsprings of type 2 diabetic Patients” evaluated 
heart rate variability (HRV) with 24 hours ECG Holter monitoring 
apparatus and found out reduction of autonomic nervous system function 
if the offsprings are insulin resistant.49 
HRV and DIABETES MELLITUS 
 Autonomic impairment in diabetes mellitus shows clinical 
manifestations long after the onset of the disease, but subclinical cardiac 
autonomic neurapathy measures could be detected by HRV very early 
much before the clinical manifestation of the disease. Reduced HRV can 
be associated with inflammation of adipose tissue and carotid artery 
atherosclerosis, in type 2 diabetes mellitus 50.  
 People having post parandial elevated blood glucose before the 
onset of diabetes mellitus had a low HRV. Autonomic imbalance can 
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produce further decline in parasympathetic tone, enhancing sympathetic 
tone during progression of pre diabetic state to type 2 diabetes mellitus.51 
HRV shows standard deviation of NN (SDNN)  measures of both 
sympathetic and parasympathetic modulation, and root mean square of 
successive differences (RMSSD). It is strongly backed by research and is 
generally considered the most accurate measure of autonomic nervous 
system activity. 
Stucky M.I et al in their findings showed that the patients with low 
HRV have an increased prevalence of complications and risk of mortality 
compared with those with normal autonomic function. These findings 
provide support for the use of HRV as a risk indicator in T2DM.46 
Thomas Benichou et al conducted a systematic review and meta 
analysis to evaluate the impact of T2D on HRV parameters. They 
concluded that T2DM was associated with an overall decrease in the HRV 
of T2DM patients. Both sympathetic and parasympathetic activity were 
decreased which can be explained by the deleterious effects of altered 
glucose metabolism on HRV leading to cardiac autonomic neuropathy.52 
John Mukesh Raja Arumugam and Annapoorna Mary in their study 
on “Heart Rate Variability a cardiac indicator in diabetic autonomic 
neuropathy; a systematic review” did a review of published clinical 
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research articles and concluded that the existing literature support that 
HRV is an effective cardiac indicator to predict cardiac morbidity and 
mortality among diabetes mellitus patients.53 
HbA1c and Diabetes 
 HbA1c measures are commonly referred to as glycosylated 
haemoglobin. The binding of hemoglobin with glucose in the blood is 
called glycosylated haemoglobin. It measures the average glucose 
concentration in the plasma. In diabetes mellitus, the amount of HbA1c is 
high referring to a poor control of blood glucose levels.54 
 The increase in glycosylated haemoglobin level can be associated 
with increased risk of developing cardiovascular complications of DM. 
The HbA1c level monitoring in type 2 diabetic patients may show more 
improvement in the outcome of disease. Normal blood glucose represents 
a normal amount of HbA1c level in blood. When plasma glucose level 
rises then the level of  HbA1c will also increase.54 
 HbA1c can measure the average blood glucose level in past three 
months. Hence the % of HbA1c is mainly determined by the level of 
plasma glucose and the lifespan of RBC.55 The measurement of 
glycosylated haemoglobin level is high in not only diabetic patients but 
also in persons suffering from other disorders like chronic renal failure 
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which is measured by ion exchange chromatography. In anaemic patients 
with autoimmune haemolytic anaemia, the measurement of glycosylated 
haemoglobin cannot be detected.  
The American Diabetic Association recommended glycosylated 
haemoglobin test atleast twice in a year for those who achieve treatment 
target and four times a year those who are not meeting the treatment 
target.56 Other than regulating glycemic control, the value of glycosylated 
haemoglobin shows improvement in the communication and 
collaborative efforts between patients and clinicians.57 
Mody is a non insulin dependent form of diabetes occurring in 
young adults at an age of 25, it is an autosomal dominant inherited 
disorder occurring due to gene mutation.58  
Obesity, physical inactivity and sedentary life style are the 
etiological agents for the development of type 2 diabetes mellitus. About 
two thirds of type 2 diabetes mellitus individuals are overweight or obese, 
if the BMI is greater than 23 kg/m2, if the BMI is greater than 40 kg/m2 
then there is  40 to 90 times higher risk of developing diabetes mellitus.59 
Truncal obesity can lead to visceral fat accumulation which can also 
predispose to the development of type 2 diabetes mellitus.60 
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Obesity, genetic factors, and low birth weight are risk parameters 
for the development of insulin resistance, when an individual becomes an 
adult.62 
The predominant function of insulin is to lower blood glucose 
levels by favouring its movement into the cells. The other activities are 
lipogenesis, protein anabolic action and regulation of ANS. Resistance 
can develop to its action.61 ‘The hyperinsulinaemic, euglycaemic clamp’ 
method is a technique to measure insulin resistance. Sensitivity of insulin 
is relatively low in type 2 diabetes mellitus.58  
Insulin inhibits platelet aggregation and also cause vasodilation of 
large arteries. So insulin resistance can predispose to atherothrombotic 
vascular lesions which is a major cause of mortality in type 2 diabetes 
mellitus.63 
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MATERIALS & METHODOLOGY 
Ethical Clearance  
Ethical clearance was obtained from institutional Human Ethics 
Committee PSG IMS & R, Coimbatore.  
Study Design 
This cross sectional study was conducted in the department of 
physiology, PSG  IMS & R, Coimbatore.  
Sample Size  
After taking informed consent, a sample size of 60 type 2 diabetes 
mellitus was analysed for HRV analysis.  
30 control group without diabetes mellitus (Offsprings of type 2 
diabetes mellitus)  
30 study group with diabetes mellitus (Offsprings of type 2 
diabetes mellitus) 
Study Population & Place of Study : 
Study population within the age group of 30 to 70 years males and 
females were recruited from Master Health Check-up PSG IMS&R, 
Coimbatore.  
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Methodology  
60 type 2 diabetes mellitus subjects were assessed according to the 
data collection tool attached in the annexure. The data collection tool is a 
protocol that has general information like name, age, sex, occupation , 
height, weight, treatment history, family history, personal history (alcohol 
/ smoking, tobacco chewing), blood pressure, duration of diabetes and 
diabetic complications . 
To analyse HRV in 30 offsprings of type 2 diabetes mellitus who 
are not diabetics. They serve as a control group. This HRV analysis is 
compared with 30 offsprings of  type 2 diabetes mellitus who are 
diabetics and they serve as study group.  
Inclusion Criteria 
• Offsprings of type 2 diabetic patients without DM (control group) 
• Offsprings of type 2 diabetes with diabetes mellitus (study group) 
• Age group 30 – 70 years 
Exclusion Criteria 
• Hypertension 
• Chronic kidney disease 
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• Rheumatoid arthritis 
• Any cardiac illness 
• Bronchial asthma 
The blood parameters like fasting blood glucose, postprandial 
blood glucose, lipid profile status and HbA1c values were collected from 
Master Health Check-up clinic of PSG IMS & R, Coimbatore. 
The other physiological variables like sex, height and weight of the 
individual, duration of diabetes, age of onset will also be noted. The body 
mass index is then calculated. 
Glycosylated Haemoglobin (HbA1c) 
Long term blood glucose control can be measured and monitored 
by an important method called HbA1c. The non-enzymatic glycation of 
haemoglobin is due to prolonged elevated blood glucose level. This 
gives a clear idea about the patients glycaemic control over the previous 
2- 3 months. All individuals with diabetes mellitus should be tested for 
HbA1c during their initial evaluation and as a part of their package along 
with other investigations like lipid profile and blood glucose for Master 
Health Check-up.  
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• Long term complications of diabetes mellitus can be detected by 
HbA1c  
• HbA1c values should mimic the short term values of blood glucose 
level. 
• Diabetes Mellitus is defined as values of HbA1c greater than 6.5 % 
(Pulse 2010) 
• HbA1c values less than 7.5 is referred to as good control.  
• HbA1c values in between 7.5 – 9.5 % are referred to as poor 
control. 
• HbA1c values of greater than 9 % is referred to as very poor 
control. 
Patients with adequate glycaemic control were told to check HbA1c 
value twice a year. Patients who were not having adequate glycaemic 
control were told to check HbA1c values every three months. 
In my study, comparison of HRV analysis with other parameters 
like lipid profile, blood glucose, glycosylated haemoglobin, Body Mass 
Index (BMI) was found out between the study and the control group. 
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Body Mass Index (BMI) 
 Standing height was measured on a clinic standiometer. Body 
weight was assessed using a calibrated weighing scale, with subjects 
using light clothes and no shoes. BMI was calculated as weight in 
kilograms divided by square of height in meters 64. They were further 
classified as per Indian council of medical research classification. 
Underweight <18.5 kg/m2, 18.6 to 24.9 kg/m2  is normal. 25 to 29.9 kg/m2  
is considered overweight and above 30 kg/m2  is considered obese 65 
The subject’s venous blood was collected by asking them to be in fasting 
for 12 hours. The serum was separated by centrifuging the blood sample 
at 3000 revolutions for 5 minutes. The enzymatic calorimetric analysis 
was done for the lipid profile parameters like cholesterol, triglyceride, 
LDL and HDL. The blood glucose levels were estimated by glucose 
oxidase method. 
HRV Procedure 
The basic principle is that beat to beat variation in SA nodal 
discharge as recorded by ECG is computed and analysed by the software 
for determination of spectral indices of HRV. 
 
32 
 
Requirements 
• All equipment equipped as required for an ECG recording  
• Software with the computer required for H-R analysis. 
Methods  
HRV can be quantified in time and frequency domain using the RR 
intervals in the 5 min lead 2 ECG. The RR- Tachogram is plotted. 
There are two types of HRV recordings : the short term 5 minutes 
HRV recording and day and night long term HRV recording. Though 
long term HRV recording is the ideal one, short term HRV recording is 
usually performed for research and clinical investigations. 
The procedure of short term recording as depicted in the Task Force 
Report on HRV. 
• The subject is asked to lie down comfortably in supine position in 
the laboratory, and ECG electrodes are connected for lead 2 ECG 
recording. 
• Positive electrode was connected to left arm, negative electrode 
was connected to right arm.  
• Ground electrode was connected to right foot.  
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• All the subjects were recorded baseline ECG and exclusion of 
abnormal baseline ECG was done . 
• After 5 minutes of supine rest, ECG signals are acquired at a rate 
of 1000 samples/ second during supine rest using data acquisition 
system, such as BIOPAC MP 100 (BIOPAC INC, USA), 
(Minimum 250 HZ sampling rate) 
• The raw ECG signals and the RR Intervals are acquired on a 
moving time base. 
• Data from BIOPAC are transferred to a windows – based PC 
loaded with software for HRV analysis, such as acknowledge 
software version 3.8.2 Ectopics and artefacts are removed from the 
recorded ECG. 
• RR Tachogram is extracted from the edited 256 sec ECG Using the 
R wave detector in the acknowledged soft ware and saved in ASC- 
2 format, which is later used offline for short – term HRV analysis  
(RR tachogram should have minimum 288 RR intervals) 
• HRV analysis is performed by using the HRV analysis software 
version 1.1 (Bio- Signal Analysis group, Finland) 
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Following parameters will be analysed after recording HRV: 
• Time domain method 
• Frequency domain method 
This method is based on the analysis of beat –to-beat variations or 
NN intervals. 
Selective Time Domain Measures of HRV Analysis: 
The time domain measures includes the variable such as  
• Mean RR Interval(NN) 
• Mean HR Interval  
• SDNN 
• pNN50 
• RMSSD 
Selective Frequency Domain Measures of HRV Analysis: 
The Frequency domain measures includes the variable such as  
• Total Power 
• LF Power (Low Frequency Power) 
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• HF Power ( High Frequency Power) 
• LF Norm 
• HF Norm 
• LF/HF Ratio 
Selective Time Domain Measures of HRV Analysis 
The time domain measures including the variable such as  
• Mean RR Interval(NN) 
This could measure the average of all NN Intervals. Mean RR 
interval is inversely proportional corresponding to mean heart rate 
in a given physiological state which could show sympathovagal 
imbalance. 
• SDNN(unit= ms)  
Standard deviation of all NN intervals could represent the measure 
of total variability  
When it represents for a low period of time, it could measure HRV 
in low and high frequency ranges. 
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• RMSSD (unit= ms)  
• The square root of the mean of the sum of the squares of the 
differences between adjacent NN intervals. 
This could show high frequency variation in heart rate and 
indicates a vagal response.  
• SDNN index(unit= ms)  
Mean of standard deviation of all NN intervals for all 5 min 
segments of the entire recording. 
• PNN50 %(unit= ms)  
NN50 count divided by the total number of all NN intervals.  
Frequency Domain Methods: 
• Heart rate variability is assessed by spectral analysis of an array of 
RR intervals. 
• The main advantage of spectral analysis of signals is the possibility 
to study their frequency specific oscillations. Thus, not only the 
amount of variability but also the oscillation frequency (number of 
heart rate fluctuations per second) can be obtained. 
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• Applications of different spectral methods were used for analysis 
of the RR tachogram. 
• Power Spectral Density (PSD) analysis gives insights on how 
power variance distribute as the function of frequency.  
Classification for Power Spectral Density  
Methods employed for the calculation of Power Spectral Density 
(PSD) are  
• Parametric methods 
• Non parametric methods 
Parametric method is the common method employed for doing 
spectral analysis, where there was diversion of the entire data which 
would have overlapping sections and there was Fast Fourier 
transformation of each section and the periodogram values were done by 
taking an average.  
The Non Parametric Method : 
Advantages are: 
• In most of the cases it is Fast Fourier transformation. 
• The speed processing is high. 
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Parametric Methods Advantages : 
• Spectral bands are smooth that can be independently distinguished 
by pre selected frequency bands. 
• The spectrum of post processing is easy with calculation done 
automatically which is of low & high frequency components of 
power, and identification is easy by the central frequency of each 
component.  
• The estimation of power spectral density (PSD) is accurate even 
for a small number of samples on which signal acquired is 
supposed to remain stationary. 
• The main advantages of parametric method is the need for 
verifying the suitability of the chosen model and its complexity. 
Independent of the different methods which were employed, only an 
estimate of the true power spectral density (PSD) of the signal could be 
acquired by proper mathematical algorithms. In most of the cases, both 
methods could give comparable results.  
The variable components of spectral analysis of frequency domain 
measures are  
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Frequency Domain Methods 
• In this method, different bands of frequency are assigned then the 
numbers of NN interval, which match the particular band are counted. 
• HRV is used as tool to assess the imbalance between the sympathetic 
and parasympathetic influence on heart rate. 
Frequency Domain Parameters: 
• Total power 
• LF power (LF) 
• HF power (HF) 
• LF norm 
• HF norm 
• LF/HF ratio 
Selective Frequency Domain Measures of HRV Analysis Calculations 
• Total power :  
The NN interval is varied over the temporal segment. It’s frequency 
range is approximately 0.4 Hertz.  
• Low Frequency power (LF): 
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The range of power is low frequency range. The frequency range is 
0.04 to 0.15 Hertz. This frequency band could represent both sympathetic 
and parasympathetic tone.  
• High Frequency power(HF): 
The range of power is a high frequency range. It’s frequency range is 
from 0.15 to 0.4 Hertz.  
• LF norm ( Nu) : 
The normalized units of low frequency power. 
LF / ( Total power – very low frequency (VLF) x 100. 
• HF Norm ( NU): 
Normalized units of High frequency power 
HF / (Total power- VLF) x 100. 
• LF / HF power ratio : 
LF/ HF ratio represents the ratio of LF to HF spectral powers. 
LF /HF Ratio is helpful in assessing the coordinated 
functioning among sympathetic and parasympathetic tone. 
When the score is decreased it could represent the decrease in 
sympathetic tone or increase in parasympathetic tone.  
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Statistical Analysis 
The statistical analysis was done using SPSS software (statistical 
package for social science version – 23) by independent sample t test for 
comparing the participants of the control group and study group. 
The descriptive statistics frequency analysis, percentage analysis 
were used for categorical variables and the mean and standard deviation 
were used for continuous variables. To assess the relationship between 
the variables like: 
• Correlation of HRV with lipid profile between control and study 
group.  
• Correlation of HRV with Body Mass Index (BMI) will be found 
out between the control and the study group. 
• Correlation of HRV with glycosylated haemoglobin will be found 
out between the control and the study group. 
 All these correlation analyses are carried out by Pearson correlation 
analysis. In all the above statistical tools the probability value <  0.05 is 
considered as significant level. 
Classification of ‘P’ Values 
P values is classified as: 
P<0.05 was considered statistically significant. 
P>0.05 was considered statistically insignificant. 
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RESULTS 
HRV analysis was done in 30 offsprings of type 2 diabetes mellitus 
who were not diabetics served as control group. This was compared with 
30 offsprings of type 2 diabetes mellitus who were diabetics (study 
group).  
The test for the control and study group were done by recording  
ECG in lead II supine position at rest for duration of 5 minutes which was 
termed as short term HRV analysis.  
From the ECG recorded  the RR interval was noted  and RR 
Tachogram was plotted.  
Comparison of HRV with other parameters like lipid profile, blood 
glucose, glycosylated haemoglobin, BMI was found out between the 
study and the control group. 
Comparison of HRV analysis of Time Domain Parameters and Frequency 
Domain Parameters was done between the control and the study groups.  
 Correlation studies were done between the HRV parameters and 
biochemical values within each control group and study group. 
 For statistical analysis, Independent sample t- test was used. To 
assess the relationship between the variables Pearson’s Correlation was 
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used and to find the significance in categorical data Chi- Square test was 
used. 
Group A  
30 offsprings of type 2 diabetes mellitus who were not diabetics 
(control group) 
Group B 
30 offsprings of type 2 diabetes mellitus who were diabetics (study 
group) 
Statistical Analysis 
The data collected was analysed by HRV analysis using software 
version 1-1 (Bio signals Analysis group, Finland). Results were tabulated 
and analysed by using Independent sample t-test.  
There exists significant difference in the mean value of the given 
variable among the controls and the study group. 
Classification of ‘P’ Values 
P values is classified as  
P value > 0.05 was denoted as statistically insignificant. 
P value < 0.5 was denoted as statistically significant. 
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Results were tabulated and analysed using Independent sample t-test. 
• These HRV analysis was analysed using Independent sample t-test 
between the study and the control groups.  
• Correlation of HRV was done with lipid profile, of study and control 
groups. 
• Correlation of HRV with body mass index was found out between of 
study and control groups. 
• Correlation of HRV with glycosylated haemoglobin was found out 
between the study and control groups. 
MAIN ANALYSIS 
COMPARISION BETWEEN CONTROL GROUP AND STUDY 
GROUP 
Baseline characteristic of 30 offsprings of type 2 diabetes mellitus 
who were not diabetics (control group) and 30 offsprings of type 2 
diabetes mellitus who were diabetics (study group) were compared.  
Results are expressed as Mean + Standard deviation (SD). 
Mean age of 30 offsprings of type 2 diabetes mellitus who are 
not diabetics (control group) and 30 offsprings of type 2 diabetes 
mellitus who were diabetics (study group)    
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 The age of the 30 controls had a mean and SD of 41.3 +  and SD 
10.55 years. The study group with diabetes had a mean and SD of 49.5 + 
10.06 years and the difference was found to have a P value of 0.003 
which was statistically   significant. This shows that the age of both the 
groups is matched in our study. Table 1. 
Comparison of Gender in 30 offsprings of type 2 diabetes mellitus 
who are not diabetics (control groups) and 30 offsprings of type 2 
diabetes mellitus who are diabetics (study group)  :  
• The distribution of gender in the control group was as follows. 
There were 8   (27%) Females and 22 (73%) males. In the study 
group there were 5 (17%) females and 25 (83%) males. Table 2   
COMPARISON OF HEART RATE VARIABILITY 
PARAMETERS BETWEEN CONTROL GROUP AND STUDY 
GROUP: 
TIME DOMAIN MEASURES: 
Mean R-R: 
 The mean + SD values of mean R-R(ms) in the  control group was   
825.65 +152.37 and in the study group was 735.86  + 120.02(ms). The 
mean value of the heart rate was decreased in the study group and the 
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difference was found to be statistically significant with a p value of  
0.01.Table 3 Chart 1. 
Mean H-R: 
 The mean + SD values of mean H-R in beats per minute in the 
control group was   74.51 +13.55 and in the study group was it 83.33 +  
14.73 beats per min. The mean value of the heart rate was increased in the 
study group and the difference was found to be statistically significant 
with a p value of 0.02.Table 4 Chart 2. 
SDNN 
 The mean +SD  values  of SDNN ms in the control groups was 
67.74 + 32.26  and in the study group was 58.43+ 17.28.  The mean value 
of the SDNN was decreased in the study group and the difference was 
found to be statistically insignificant with   p value of 0.17.  Table 5  
Chart 3. 
RMSSD  
            The mean + SD values of RMSSD (ms) in the control groups was 
25.77+ 17.16 and in the study group was 15.99 + 7.73. There was 
decrease in the mean value of RMSSD in the  study group. The difference 
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was found to be statistically   significant with   p value of 0.01 Table 6  
Chart 4. 
pNN50 
           The mean + SD  values  of pNN50 (ms) in the control groups was 
3.69 + 5.31  and in the  study group was 0.85 + 1.84.There was decrease 
in the  mean value of  pNN50 in the study group. The difference was 
found to be statistically significant with p value of 0.01.Table 7  Chart 5. 
FREQUENCY DOMAIN MEASURES: 
Comparison of frequency domain measures of heart rate variability 
parameters in control and study group: 
  Three frequency domain measures have been compared between 
control group and study group. 
 Low Frequency Power (LF nu) 
 Low frequency power LF is measured in normalized units (nu) 
The mean + SD values of LF  nu  in the control group was 45.13+ 
13.87 and in the  study group was 46.26 + 16.25. The mean value of  LF 
nu  was increased  in the study group and  the difference was found to be 
statistically is insignificant with the p value of 0.77  Table 8  Chart 6. 
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 High Frequency Power (HF nu) 
 High frequency power HF is measured in normalized units (nu). 
The mean + SD values of HF nu  in the control groups was 54.87+ 13.87 
and in  the  study group it was  54.74 + 15.92. The mean value of   HF nu 
was slightly decreased in the study group and the difference was found to 
be statistically insignificant  with the p value of 0.97.  Table 9  Chart 7.          
LF/HF ratio 
The mean + SD  values  of  LF/HF  ratio  in the control groups was 
0.97 + 0.68 and  the  study group was 1.04 + 0 .83. The  mean value of   
LF/HF  ratio  in the study group it was increased  when compared to the 
control group and the difference was found to be statistically insignificant  
with the p value of 0.72 Table 10  Chart 8.    
COMPARISON OF BIOCHEMICAL PARAMETERS BETWEEN 
CONTROL GROUP AND STUDY GROUP: 
HbA1c Table     
 The mean + SD values  of  HbA1c  in the control group was  5.55 + 
0.34 and in the study group it was  8.63 + 2.70 measured in % and there 
is a marked difference in the mean values of  two groups which shows 
their glycaemic status. The mean value of HbA1c is much increased in 
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study group denoting the diabetic status. HbA1c in the study group it was 
increased when compared to the control group and the difference was 
found to be statistically significant  with the p value of  0.00.  Table 11  
Chart 9.    
Cholesterol 
 The mean + SD values  of  cholesterol  in the control group was  
188.33 + 34.73 and in the study group it was  187.87 + 35.09 measured in 
mg/dl. Cholesterol in the study group was decreased when compared to 
the control group and the difference was found to be statistically 
insignificant with the p value of 0.96. Table 12 Chart 10.    
Triglycerides 
 The mean + SD values of  triglycerides  in the control group was  
117.10 + 56.15 and in the study group it was  194.33 + 128.25  measured 
in mg/dl. There was a marked increase in the mean values of  study group 
compared to the control group and the difference was found to be 
statistically significant  with the p value of  0.00.  Table 13 Chart 11.    
High Density Lipoprotein Cholesterol (HDL-C) 
 The mean + SD values  of  high density lipoprotein   in the control 
group was  44.43 + 11.66 and in the study group it was  37.13 + 8.68  
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measured in mg/dl. High density lipoprotein   in the study group was 
decreased when compared to the control group and the difference was 
found to be statistically significant with the p value of  0.01. Table 14 
Chart 12.   
Low Density Lipoprotein Cholesterol (LDL-C) 
 The mean + SD  values  of  low density lipoprotein  in the control 
group was  140.43 + 33.67 and in the study group it was  138.10 + 35.44 
measured in mg/dl. Low density lipoprotein in the study group was 
decreased when compared to the control group and the difference was 
found to be statistically insignificant with the p value of  0.8 Table 15 
Chart 13.   
Glucose Fasting  
 The mean  + values of  glucose fasting in the control group was 
97.90  + 10.05 and in the study group was 178.37  +74.43 measured in 
mg/dl. The  fasting blood glucose is increased in the study group when 
compared to the control group and the difference was found to be 
statistically  significant with the p value of 0.00 Table 16 Chart 14. 
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Post Prandial Blood Sugar (PPBS) 
 The mean  + values of  post prandial blood sugarin the control 
group was 125.40  + 19.00 and in the study group was 263.77  + 102.15 
Post prandial blood sugar is increased in the study group when compared 
to the control group and the difference was found to be statistically  
significant with the p value of 0.00. Table 17 Chart 15. 
Body Mass Index (BMI) 
The mean  + values of  body mass indexin the control group was 
26.093+4.6066 and in the study group was 25.200+3.3143 body mass 
index is increased in the study group when compared to the control group 
and the difference was found to be statistically  significant with the p 
value of 0.39. Table 18 Chart 16. 
PEARSON'S CORRELATION (TIME DOMAIN MEASURES) 
HbA1c and mean RR in control group and study group : TABLE - 19 
There was a negative correlations between HBA1c and mean RR 
in control group (r=-0.24,p=0.21) which was statistically  insignificant. 
There was a negative correlations between HBA1c and mean RR in 
study group (r=-0.10,p=0.61) which was statistically  insignificant.  
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HbA1c and mean HR in control group and study group : TABLE - 19 
There was a positive correlations between HbA1c and mean HR in 
control group (r=0.22,p=0.25) which was statistically  insignificant. 
There was a positive  correlations between HbA1c and mean HR in study 
group (r=0.05, p=0.79) which was statistically  insignificant.  
HbA1c and SDNN in control group and study group : TABLE - 19 
There was a negative correlations between HbA1c and SDNN in 
control group (r=-0.16,p=0.39) which was statistically insignificant. 
There was a negative correlations between HbA1c and SDNN in study 
group (r=-0.13,p=0.48) which was statistically  insignificant.  
HbA1c and RMSSD in control group and study group : TABLE - 19 
There was a negative correlations betweenHbA1c and RMSDD  in 
control group (r=-0.11,p=0.56) which was statistically insignificant. 
There was a positive correlations between HbA1c and RMSSD in study 
group (r=0.01,p=0.96) which was statistically insignificant.  
HbA1c and pNN50 in control group and study group : TABLE - 19 
There was a negative correlations between HbA1c and pNN50 in 
control group (r=-0.12,p=0.53) which was statistically  insignificant. 
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There was a positive correlations between HbA1c and pNN50 in study 
group (r=0.08,p=0.69) which was statistically  insignificant.  
Correlations Analysis of HRV Parameters (Frequency  Domain 
Measures) and HbA1c between the study group and the control 
group. 
HbA1c and LF nu control group and study group : TABLE - 20 
There was a negative correlation between HbA1c and LF nu in 
control group (r=-0.54,p=0.78) which was statistically  insignificant. 
There was a positive correlations between HbA1c and LF nu  in study 
group (r=0.32,p=0.09) which was statistically insignificant.  
HbA1c and HF nu control group and study group : TABLE - 20 
There was a positive correlations between HbA1c and HF nu in 
control group (r=0.54,p=0.78) which was statistically  insignificant. 
There was a negative correlations between HbA1c and HF nu in study 
group (r=-0.39,p=0.04) which was statistically  significant.  
HbA1c and LF/HF RATIO  control group and study group :   
TABLE - 20 
There was a negative correlations between HbA1c and LF/HF 
RATIO  in control group (r=-0.11,p=0.56) which was statistically  
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insignificant. There was a positive correlations between HbA1c and 
LF/HFRATIO in study group (r=0.51,p=0.00) which was statistically  
significant.  
Correlations Analysis of HRV Parameters (Time Domain Measures) 
and triglycerides between the study group and the control group. 
Triglycerides and mean RR in control group and study group :        
TABLE - 21 
There was a negative correlations between triglycerides and mean 
RR in control group (r=-0.21,p=0.27) which was statistically  
insignificant. There was a positive correlations between triglycerides and 
mean RR in study group (r=0.00,p=0.99) which was statistically 
insignificant.  
Triglycerides and mean HR in control group and study group :       
TABLE - 21 
There was a positive correlations between triglycerides and mean 
HR in control group (r=0.22,p=0.24) which was statistically  
insignificant. There was a negative correlations between triglycerides and 
mean HR in study group (r=-0.07,p=0.71) which was statistically  
insignificant. 
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Triglycerides and SDNN in control group and study group :      
TABLE - 21 
There was a negative correlations between triglycerides and 
SDNN in control group (r=-0.09,p=0..64) which was statistically 
insignificant. There was a positive correlations between triglycerides and 
SDNN in study group (r=0.07,p=0.73) which was statistically 
insignificant. 
Triglycerides and RMSSD in control group and study group : 
TABLE - 21 
There was a negative correlations between triglycerides and 
RMSDD  in control group (r=-0.14,p=0.45) which was statistically 
insignificant. There was a positive correlation between triglycerides and 
RMSDD  in study group (r=0.06,p=0.74) which was statistically 
insignificant. 
Triglycerides and pNN50 in control group and study group :        
TABLE - 21 
There was a negative correlations between triglycerides and 
pNN50 in control group (r=-0.18,p=0.34) which was statistically  
insignificant. There was a positive correlation between triglycerides and 
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pNN50 in study group (r=0.04,p=0.84) which was statistically  
insignificant. 
Correlations Analysis of HRV Parameters (Frequency Domain 
Measures) and triglycerides between the study group and the control 
group. 
Triglycerides and LF nu control group and study group :           
TABLE - 22 
There was a positive correlations between triglycerides and LF nu 
in control group (r=0.04,p=0.85) which was statistically  insignificant. 
There was a positive correlations between triglycerides and LF nu in 
study group (r=0.27,p=0.16) which was statistically  insignificant. 
Triglycerides and HF nu control group and study group :        
TABLE - 22 
There was a negative correlations between  triglycerides and HF 
nu in control group (r=-0.04,p=0.85) which was statistically  
insignificant. There was a negative correlations between  triglycerides 
and HF nu in study group         (r=-0.29,p=0.12) which was statistically  
significant. 
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Triglycerides and LF/HF RATIO control group and study group :   
TABLE - 22 
There was a negative correlations between triglycerides and 
LF/HF RATIO in control group (r=-0.06,p=0.77) which was statistically  
insignificant. There was a positive correlations between triglycerides and 
LF/HF RATIO in study group (r=0.18,p=0.33) which was statistically  
insignificant. 
Correlations Analysis of HRV Parameters (Time Domain Measures)  
Cholesterol and mean RR in control group and study group : 
TABLE - 23 
There was a negative correlations between cholesterol and mean 
RR in control group (r=-0.22,p=0.24) which was statistically  
insignificant. There was a negative correlations between cholesterol and 
mean RR in study group (r=-0.04,p=0.83) which was statistically  
insignificant.  
Cholesterol and mean HR in control group and study group : 
TABLE - 23 
There was a positive correlations between cholesterol and mean 
HR in control group (r=0.21,p=0.27) which was statistically  
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insignificant. There was a negative correlations between cholesterol and 
mean HR in study group (r=-0.10,p=0.61) which was statistically  
insignificant.  
Cholesterol and SDNN in control group and study group :           
TABLE - 23 
There was a negative correlations between cholesterol and SDNN 
in control group (r=-0.06,p=0.75) which was statistically insignificant. 
There was a positive correlations between cholesterol and SDNN in 
study group (r=0.20,p=0.28) which was statistically insignificant. 
Cholesterol and RMSSD in control group and study group :        
TABLE - 23 
There was a negative correlations between cholesterol and 
RMSDD in control group (r=-0.09,p=0.65) which was statistically 
insignificant. There was a positive correlations between cholesterol and 
RMSDD in study group (r=0.07,p=0.72) which was statistically 
insignificant. 
Cholesterol and pNN50 in control group and study group :        
TABLE - 23 
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There was a negative correlations between cholesterol and pNN50 
in control group (r=-0.12,p=0.54) which was statistically  insignificant. 
There was a positive correlations between cholesterol and pNN50 in 
study group (r=0.13,p=0.50) which was statistically  insignificant. 
Correlations Analysis of HRV Parameters (Frequency  Domain 
Measures) and Cholesterol between the study group and the control 
group. 
Cholesterol and LF nu control group and study group : TABLE - 24 
There was a positive correlations between cholesterol and LF nu 
in control group (r=0.07,p=0.72) which was statistically  insignificant. 
There was a positive correlations between cholesterol and LF nu in 
study group (r=0.39,p=0.03) which was statistically  insignificant. 
Cholesterol and HF nu control group and study group : TABLE - 24 
There was a negative correlations between cholesterol and HF nu 
in control group (r=-0.07,p=0.72) which was statistically  insignificant. 
There was a negative correlations between cholesterol and HF nu in 
study group (r=-0.33,p=0.08) which was statistically  insignificant. 
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Cholesterol and LF/HF RATIO  control group and study group : 
TABLE - 24 
There was a positive correlations between cholesterol and LF/HF 
RATIO  in control group (r=0.07,p=0.72) which was statistically  
insignificant. There was a positive correlations between cholesterol and 
LF/HF RATIO  in study group (r=0.32,p=0.08) which was statistically  
insignificant 
Correlations Analysis of HRV Parameters (Time Domain Measures] 
LDL cholesterol and mean RR in control group and study group :  
TABLE - 25 
There was a negative correlations between LDL  cholesterol and 
mean RR in control group (r=-0.24,p=0.19) which was statistically  
insignificant. There was a negative correlations between LDL 
cholesterol and mean RR in study group (r=-0.06,p=0.77) which was 
statistically  insignificant. 
LDL cholesterol and mean HR in control group and study group :  
TABLE - 25 
There was a positive correlations between LDL  cholesterol and 
mean HR in control group (r=0.23,p=0.22) which was statistically  
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insignificant. There was a positive correlations between LDL  
cholesterol and mean HR in study group (r=-0.06,p=0.77) which was 
statistically  insignificant.  
LDL cholesterol and SDNN in control group and study group :        
TABLE - 25 
There was a negative correlations between LDL  cholesterol and 
SDNN in control group (r=-0.07,p=0.71) which was statistically 
insignificant. There was a positive correlations between LDL cholesterol 
and SDNN in study group (r=0.15,p=0.43) which was statistically 
insignificant. 
LDL  cholesterol and RMSSD in control group and study group :  
TABLE - 25 
There was a negative correlations between LDL  cholesterol and 
RMSDD in control group (r=-0.10,p=0.61) which was statistically 
insignificant. There was a positive correlations between LDL  
cholesterol and RMSDD  in study group (r=0.06,p=0.75) which was 
statistically insignificant. 
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LDL cholesterol and pNN50 in control group and study group :      
TABLE - 25 
There was a negative correlations between LDL  cholesterol and 
pNN50 in control group (r=-0.13,p=0.48) which was statistically  
insignificant. There was a positive correlations between LDL  
cholesterol and pNN50 in study group (r=0.13,p=0.51) which was 
statistically  insignificant. 
Correlations Analysis of HRV Parameters (Frequency  Domain 
Measures) and LDL  cholesterol between the study group and the 
control group. 
LDL  cholesterol and LF nu control group and study group :   
TABLE - 26 
There was a positive correlations between LDL  cholesterol and 
LF nu  in control group (r=0.07,p=0.72) which was statistically  
insignificant. There was a positive correlations between LDL  
cholesterol and LF nu  in study group (r=0.27,p=0.15) which was 
statistically  insignificant. 
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LDL and HF nu control group and study group : TABLE – 26 
There was a negative correlations between LDL  cholesterol and 
HF nu in control group (r=-0.07,p=0.72) which was statistically  
insignificant There was a negative correlations between LDL  
cholesterol and HF nu in study group (r=-0.20,p=0.29) which was 
statistically  insignificant. 
LDL and LF/HF RATIO  control group and study group :         
TABLE - 26 
There was a positive correlations between LDL  cholesterol and 
LF/HF RATIO  in control group (r=0.05,p=0.81) which was statistically  
insignificant. There was a positive correlations between LDL  
cholesterol and LF/HF RATIO  in study group (r=0.21,p=0.27) which 
was statistically  insignificant. 
Correlations Analysis of HRV Parameters (Time Domain Measures] 
HDL cholesterol and mean RR in control group and study group :   
TABLE - 27 
There was a positive correlations between HDL cholesterol and 
mean RR in control group (r=0.11,p=0.58) which was statistically  
insignificant. There was a positive correlations between HDL cholesterol 
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and mean RR in study group (r=0.02,p=0.91) which was statistically  
insignificant. 
HDL cholesterol and mean HR in control group and study group : 
TABLE- 27 
There was a negative correlations between HDL cholesterol and 
mean HR in control group (r=-0.11,p=0.59) which was statistically  
insignificant. There was a negative correlations between HDL 
cholesterol and mean HR in study group (r=-0.01,p=0.97) which was 
statistically  insignificant.  
HDL cholesterol and SDNN in control group and study group: 
TABLE -27 
There was a positive correlations between HDL cholesterol and 
SDNN in control group (r=0.03,p=0.90) which was statistically 
insignificant. There was a positive correlations between HDL cholesterol 
and SDNN in study group (r=0.04,p=0.83) which was statistically 
insignificant. 
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HDL cholesterol and RMSSD in control group and study group:    
TABLE-27 
There was a positive correlations between HDL cholesterol and 
RMSDD in control group (r=0.89,p=0.65) which was statistically 
insignificant. There was a negative correlations between HDL 
cholesterol and RMSDD  in study group (r=-0.11,p=0.56) which was 
statistically insignificant.  
HDL cholesterol and pNN50 in control group and study group :       
TABLE - 27 
There was a positive correlations between HDL cholesterol and 
pNN50 in control group (r=0.14,p=0.48) which was statistically  
insignificant. There was a positive correlations between HDL cholesterol 
and pNN50 in study group (r=0.02,p=0.91) which was statistically  
insignificant. 
Correlations Analysis of HRV Parameters (Frequency  Domain 
Measures) and HDL cholesterol between the study group and the 
control group. 
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HDL cholesterol and LF nu control group and study group :          
TABLE - 28 
There was a negative correlations between HDL cholesterol and 
LF nu in control group (r=-0.03,p=0.89) which was statistically  
insignificant. There was a positive correlations between HDL cholesterol 
and LF nu in study group (r=0.08,p=0.69) which was statistically  
insignificant. 
HDL cholesterol and HF nu control group and study group :   
TABLE - 28 
There was a positive correlations between HDL cholesterol and 
HF nu in control group (r=0.03,p=0.89) which was statistically  
insignificant. There was a negative correlations between HDL 
cholesterol and HF nu in study group (r=-0.07,p=0.71) which was 
statistically  insignificant. 
HDL cholesterol and LF/HF RATIO control group and study group : 
TABLE - 28 
There was a negative correlations between HDL cholesterol and 
LF/HF RATIO in control group (r=-0.02,p=0.91) which was statistically  
insignificant. There was a positive correlations between HDL cholesterol 
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and LF/HF RATIO in study group (r=0.12,p=0.51) which was 
statistically  insignificant. 
Correlations Analysis of HRV Parameters (Time Domain Measures) 
and Body Mass Index between the study group and the control 
group. 
BMI and mean RR in control group and study group : TABLE - 29 
There was a negative correlations between BMI and mean RR in 
control group (r=-0.11,p=0.56) which was statistically  insignificant. 
There was a positive correlations between BMI and mean RR in study 
group (r=0.03,p=0.87) which was statistically  insignificant.  
BMI and mean HR in control group and study group : TABLE - 29 
There was a positive correlations between BMI and mean HR in 
control group (r=0.14,p=0.45) which was statistically  insignificant. 
There was a negative correlations between BMI and mean HR in study 
group  (r=-0.13,p=0.48) which was statistically  insignificant. 
BMI and SDNN in control group and study group : TABLE - 29 
There was a negative correlations between BMI and SDNN in 
control group (r=-0.14,p=0.45) which was statistically insignificant. 
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There was a negative correlations between BMI and SDNN in study 
group (r=-0.01,p=0.97) which was statistically insignificant. 
BMI and RMSSD in control group and study group : TABLE - 29 
There was a negative correlations between BMI and RMSDD  in 
control group (r=-0.12,p=0.52) which was statistically insignificant. 
There was a negative correlations between BMI and RMSDD  in study 
group (r=-0.17,p=0.38) which was statistically insignificant. 
BMI and pNN50 in control group and study group : TABLE - 29 
There was a negative correlations between BMI and pNN50 in 
control group (r=-0.13,p=0.49) which was statistically  insignificant. 
There was a negative correlations between BMI and pNN50 in study 
group (r=-0.17,p=0.36) which was statistically  insignificant. 
Pearson's Correlation test between Body Mass Index and  Frequency 
Domain Measures 
Correlations Analysis of HRV Parameters (Frequency  Domain 
Measures) and BMI between the study group and the control group. 
BMI and LF nu control group and study group : TABLE - 30 
There was a negative correlations between BMI and LF nu in 
control group (r=-0.02,p=0.90) which was statistically  insignificant. 
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There was a positive correlations between BMI and LF nu in study group 
(r=0.09,p=0.66) which was statistically  insignificant. 
BMI and HF nu control group and study group : TABLE - 30 
There was a positive correlations between BMI and HF nu in 
control group (r=0.02,p=0.90) which was statistically  insignificant. 
There was a negative correlations between BMI and HF nu in study 
group (r=-0.07,p=0.73) which was statistically  insignificant. 
BMI and LF/HF RATIO  control group and study group :         
TABLE - 30 
There was a negative correlations between BMI and LF/HF 
RATIO  in control group (r=-0.06,p=0.76) which was statistically  
insignificant. There was a positive correlations between BMI and LF/HF 
RATIO in study group (r=0.08,p=0.69) which was statistically  
insignificant. 
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TABLE - 1 
AGE 
COMPARISON OF AGE BETWEEN CONTROLS AND 
CASES 
 
 
 
 
N Mean 
Std. 
Deviation 
P value 
Age Control 30 41.3000 10.55413 0.003* 
Cases 30 49.5000 10.06102  
 
p value is 0.003 
* Statistically significant  
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TABLE – 2 
COMPARISON OF GENDER BETWEEN CONTROLS 
AND CASES 
 
 
Control/ cases 
Total 
P value 
Control Cases 
Gender Male 22 25 47 0.53 
Female 8 5 13  
Total 30 30 60  
 
p value is 0.53 
 Statistically not significant  
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TABLE - 3 
COMPARISON OF MEAN RR BETWEEN CONTROLS 
AND CASES 
 
Mean RR  (ms) Control/ 
Cases 
N Mean 
Std. 
Deviation 
P value 
Control 30 825.6507 152.36813 0.01* 
Cases 30 735.8607 120.02056  
 
p value is 0.01 
* Statistically significant  
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TABLE - 4 
COMPARISON OF MEAN HR BETWEEN CONTROLS 
AND CASES 
 
 
 
Control/ 
Cases N Mean 
Std. 
Deviation P value 
Mean H-R 
(bpm) 
Control 30 74.5110 13.54621 0.02* 
Cases 30 83.3250 14.72590  
 
p value is 0.02.  
* Statistically significant  
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TABLE - 5 
 
COMPARISON OF SDNN BETWEEN CONTROLS AND 
CASES 
 
 Control/ 
Cases N Mean 
Std. 
Deviation P value 
SDNN Control 30 67.7430 32.25802 0.17 
Cases 30 58.4283 17.28342  
 
p value is 0.17. 
 Statistically insignificant  
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TABLE - 6 
COMPARISON OF RMSSD BETWEEN CONTROLS AND 
CASES 
 
RMSSD Control/ 
Cases 
N Mean 
Std. 
Deviation 
P value 
Control 30 25.7707 17.16386 0.01* 
Cases 30 15.9914 7.72673  
 
p value is 0.01 
* Statistically significant  
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TABLE - 7 
COMPARISON OF pNN50 BETWEEN CONTROLS AND 
CASES 
 
 
pNN50  Control/ 
Cases 
N Mean 
Std. 
Deviation 
P value 
Control 30 3.6909 5.31307 0.01* 
Cases 30 0.8527 1.84265  
 
p value is 0.01 
* Statistically significant  
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TABLE - 8 
COMPARISON OF LF nu BETWEEN CONTROLS AND 
CASES 
 
 Control/ 
Cases N Mean 
Std. 
Deviation P value 
 LF nu Control 30 45.1338 13.86787 0.77 
Cases 30 46.2608 16.24778  
 
p value is 0.77.  
Statistically insignificant  
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TABLE - 9 
COMPARISON OF HFnu BETWEEN CONTROLS AND 
CASES 
 
 Control/ 
Cases 
N Mean 
Std. 
Deviation 
P value 
HF  nu Control 30 54.8662 13.86787 0.97 
Cases 30 54.7392 15.91796  
 
p value is 0.97.  
Statistically insignificant  
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TABLE - 10 
COMPARISON OF LF/HF BETWEEN CONTROLS AND 
CASES 
 
LF/HF 
Ratio  
Control/ 
Cases N Mean 
Std. 
Deviation P value 
Control 30 0.9730 0.68397 0.72 
Cases 30 1.0429 0.83125  
 
p value is 0.72.  
 Statistically insignificant  
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TABLE - 11 
 
COMPARISON OF Hb A1c BETWEEN CONTROLS AND 
CASES 
 
 
 Control/ 
Cases N Mean 
Std. 
Deviation P value 
HB A1C%  Control 30 5.5467 0.33706 .00* 
Cases 30 8.6300 2.70200  
 
p value is 0.00 
* Statistically significant  
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TABLE - 12 
COMPARISON OF CHOLESTEROL BETWEEN 
CONTROLS AND CASES 
 
 Control/ 
Cases N Mean 
Std. 
Deviation P value 
Cholesterol mg/dl Control 30 188.3333 34.72685 0.96 
Cases 30 187.8667 35.09174  
 
p value is 0.96. 
Statistically insignificant  
 
 
 
 
 
82 
 
 
 
TABLE - 13 
COMPARISON OF TRIGLYCERIDES BETWEEN 
CONTROLS AND CASES 
 
 Control/ 
Cases N Mean 
Std. 
Deviation P value 
Triglycerides mg/dl Control 30 117.1000 56.15456 0.00* 
Cases 30 194.3333 128.25253  
 
p value is 0.00. 
* Statistically significant  
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TABLE - 14 
COMPARISON OF HDL CHOLESTEROL BETWEEN 
CONTROLS AND CASES 
 
 Control/ 
Cases N Mean 
Std. 
Deviation P value 
HDL Cholesterol  
mg/dl 
Control 30 44.4333 11.66392 0.01* 
Cases 30 37.1333 8.67709  
 
p value is 0.01. 
* Statistically significant  
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TABLE - 15 
COMPARISON OF LDL CHOLESTEROL BETWEEN 
CONTROLS AND CASES 
 
 Control/ 
Cases N Mean 
Std. 
Deviation P value 
LDL Cholesterol 
mg/dl 
Control 30 140.4333 33.66845 0.8 
Cases 30 138.1000 35.44335  
 
p value is 0.8 
 Statistically insignificant  
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TABLE - 16 
COMPARISON OF GLUCOSE FASTING BETWEEN 
CONTROLS AND CASES 
 
 Control/ 
Cases 
N Mean 
Std. 
Deviation 
P value 
Glucose fasting 
mg/dl 
Control 30 97.9000 10.04593 0.00* 
Cases 30 178.3667 74.43279  
 
p value is 0.00. 
* Statistically significant  
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TABLE - 17 
COMPARISON OF POST PRANDIAL BLOOD SUGAR 
BETWEEN CONTROLS AND CASES 
 
P.P.B.S 
mg/dl 
Control/ 
Cases 
N Mean Std. Deviation P value 
Control 30 125.4000 19.00381 0.00* 
Cases 30 263.7667 102.15225  
 
p value is 0.00. 
* Statistically significant  
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TABLE - 18 
COMPARISON OF BODY MASS INDEXBETWEEN 
CONTROLS AND CASES 
 
 Control/ 
Cases 
N Mean 
Std. 
Deviation 
P value 
BMI Control 30 26.093 4.6066 0.39 
Cases 30 25.200 3.3143  
 
 
 
P value is 0.39.  
Statistically in significant  
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TABLE - 19 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(TIME DOMAIN MEASURES) AND HBA1C BETWEEN 
THE STUDY GROUP AND THE CONTROL GROUP 
HbA1c 
 
 
Time  
 Domain 
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
Mean RR -0.24 0.21 0.1 0.61 
Mean HR 0.22 0.25 0.05 0.79 
SDNN -0.16 0.39 -0.13 0.48 
RMSSD -0.11 0.56 0.01 0.96 
pNN50 -0.12 0.53 0.08 0.69 
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TABLE - 20 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(FREQUENCY DOMAIN MEASURES) AND HbA1c 
 BETWEEN THE STUDY GROUP AND THE CONTROL 
GROUP 
 
HbA1c 
 
 
Frequency  
 Domain  
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
LF (nu) -0.54 0.78 0.32 0.09 
HF (nu) 0.54 0.78 -0.39 0.04 
LF/HF ratio -0.11 0.56 0.51 0.00 
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TABLE - 21 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(TIME DOMAIN MEASURES) AND TRIGLYCERIDES 
BETWEEN THE STUDY GROUP AND THE CONTROL 
GROUP 
Triglycerides 
 
 
Time  
 Domain 
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
Mean RR -0.21 0.27 0.00 0.99 
Mean HR 0.22 0.24 0.07 0.71 
SDNN -0.09 0.64 0.07 0.73 
RMSSD -0.14 0.45 0.06 0.74 
pNN50 -0.18 0.34 0.04 0.84 
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TABLE - 22 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(FREQUENCY DOMAIN MEASURES) AND 
TRIGLYCERIDES BETWEEN THE STUDY GROUP 
AND THE CONTROL GROUP 
 
Triglycerides  
 
Frequency  
 Domain  
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
LF (nu) 0.04 0.85 0.27 0.16 
HF (nu) -0.04 0.85  - 0.29 0.12 
LF/HF ratio -0.06 0.77 0.18 0.33 
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TABLE - 23 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(TIME DOMAIN MEASURES) CHOLESTEROL 
BETWEEN THE STUDY GROUP AND THE CONTROL 
GROUP 
 
Cholesterol 
 
 
Time  
 Domain 
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
Mean RR -0.22 0.24 -0.04 0.83 
Mean HR 0.21 0.27 -0.10 0.61 
SDNN -0.06 0.75 0.2 0.28 
RMSSD -0.09 0.65 0.07 0.72 
pNN50 -0.12 0.54 0.13 0.50 
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TABLE - 24 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(FREQUENCY DOMAIN MEASURES) AND 
CHOLESTEROL BETWEEN THE STUDY GROUP AND 
THE CONTROL GROUP 
Cholesterol  
 
Frequency  
 Domain  
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
LF (nu) 0.07 0.72 0.39 0.03 
HF (nu) -0.07 0.72 -0.33 0.08 
LF/HF ratio 0.07 0.72 0.32 0.08 
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TABLE - 25 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(TIME DOMAIN MEASURES) LDLCHOLESTEROL 
BETWEEN THE STUDY GROUP AND THE CONTROL 
GROUP 
LDLCholesterol 
 
 
Time  
 Domain 
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
Mean RR -0.24 0.19 -0.06 0.77 
Mean HR 0.23 0.22 0.06 0.77 
SDNN -0.07 0.71 0.15 0.43 
RMSSD -0.10 0.61 0.06 0.75 
pNN50 -0.13 0.48 0.13 0.51 
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TABLE - 26 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(FREQUENCY DOMAIN MEASURES) AND LDL 
CHOLESTEROL BETWEEN THE STUDY GROUP AND 
THE CONTROL GROUP 
LDL Cholesterol  
 
Frequency  
 Domain  
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
LF (nu) 0.07 0.72 0.27 0.15 
HF (nu) -0.07 0.72 -0.20 0.29 
LF/HF ratio 0.05 0.81 0.21 0.27 
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TABLE - 27 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(TIME DOMAIN MEASURES) HDLCHOLESTEROL 
BETWEEN THE STUDY GROUP AND THE CONTROL 
GROUP 
HDLCholesterol 
 
 
Time  
 Domain 
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
Mean RR 0.11 0.58 0.02 0.91 
Mean HR -0.11 0.59 -0.01 0.97 
SDNN 0.03 0.90 0.04 0.83 
RMSSD 0.89 0.65 -0.11 0.56 
pNN50 0.14 0.48 0.02 0.91 
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TABLE - 28 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(FREQUENCY DOMAIN MEASURES) AND HDL 
CHOLESTEROL BETWEEN THE STUDY GROUP AND 
THE CONTROL GROUP 
HDL Cholesterol  
 
Frequency  
 Domain  
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
LF (nu) -0.03 0.89 0.08 0.69 
HF (nu) 0.03 0.89 -0.07 0.71 
LF/HF ratio -0.02 0.91 0.12 0.51 
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TABLE - 29 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(TIME DOMAIN MEASURES) BMI BETWEEN THE 
STUDY GROUP AND THE CONTROL GROUP 
BMI 
 
 
Time  
 Domain 
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
Mean RR -0.11 0.56 0.03 0.87 
Mean HR 0.14 0.45 -0.13 0.48 
SDNN -0.14 0.45 -0.01 0.97 
RMSSD -0.12 0.52 -0.17 0.38 
pNN50 -0.13 0.49 -0.17 0.36 
 
 
 
 
 
 
99 
 
 
 
TABLE - 30 
CORRELATIONS ANALYSIS OF HRV PARAMETERS 
(FREQUENCY DOMAIN MEASURES) AND BMI 
BETWEEN THE STUDY GROUP AND THE CONTROL 
GROUP 
BMI 
 
Frequency  
 Domain  
Measures 
 
Control group 
 
Study group 
Correlation 
coefficient(r) 
P value Correlation 
coefficient(r) 
P value 
LF (nu) -0.02 0.90 0.09 0.66 
HF (nu) 0.02 0.90 -0.07 0.73 
LF/HF ratio -0.06 0.76 0.08 0.69 
 
 
 
 
 
 
CHART - 1 
COMPARISON OF MEAN RR  (ms)  BETWEEN 
CONTROLS AND CASES 
 
 
 
p value is 0.01 
* Statistically significant  
 
 
 
CHART - 2 
COMPARISON OF MEAN H-R   BETWEEN CONTROLS 
AND CASES 
 
 
p value is 0.02 
* Statistically significant 
 
CHART - 3 
COMPARISON OF SDNN BETWEEN CONTROLS AND 
CASES 
 
 
 
 
 
p value is 0.17. 
Statistically insignificant  
 
 
CHART - 4 
COMPARISON OF RMSSD   BETWEEN CONTROLS 
AND CASES 
 
 
 
 
p value is 0.01 
* Statistically significant   
 
CHART - 5 
COMPARISON OF pNN50  INTERVEL BETWEEN 
CONTROLS AND CASES 
 
 
 
p value is 0.01 
* Statistically significant  
 
 
CHART - 6 
 
COMPARISON OF LF nu  BETWEEN CONTROLS AND 
CASES 
 
 
p value is 0.77.  
 Statistically insignificant  
 
 
CHART - 7 
 
COMPARISON OF HF nu  BETWEEN CONTROLS AND 
CASES 
 
 
 
 
p value is 0.97.  
 Statistically insignificant  
 
 
CHART - 8 
COMPARISON OF LF/HF RATIO  BETWEEN 
CONTROLS AND CASES 
 
 
 
p value is 0.72 
 Statistically insignificant. 
 
 
CHART - 9 
COMPARISON OF Hb A1c BETWEEN CONTROLS AND 
CASES 
 
 
 
 
p value is 0.00 
* Statistically significant 
 
 
CHART - 10 
COMPARISON OF CHOLESTEROL BETWEEN 
CONTROLS AND CASES 
 
 
 
 
p value is 0.96 
 Statistically insignificant  
 
 
CHART - 11 
COMPARISON OF TRIGLYCERIDES BETWEEN 
CONTROLS AND CASES 
 
 
 
 
 
p value is 0.00 
* Statistically significant  
 
CHART - 12 
COMPARISON OF HDL CHOLESTEROL  BETWEEN 
CONTROLS AND CASES 
 
 
 
p value is 0.01 
* Statistically significant  
 
CHART - 13 
COMPARISON OF LDL CHOLESTEROL BETWEEN 
CONTROLS AND CASES 
 
 
 
  p. value is 0.80 
 Statistically insignificant 
 
CHART - 14 
COMPARISON OF GLUCOSE FASTING (PLASMA) 
BETWEEN CONTROLS AND CASES 
 
 
 
 
 
 
p value is 0.00 
* Statistically significant  
 
CHART - 15 
COMPARISON OF POST PRANDIAL BLOOD SUGAR 
BETWEEN CONTROLS AND CASES 
 
 
 
 
 
p value is 0.00 
* Statistically significant  
 
CHART - 16 
COMPARISON OF BODY MASS INDEX BETWEEN 
CONTROLS AND CASES 
 
 
 
p value is 0.39 
Statistically insignificant  
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DISCUSSION  
Variations in heart rate is a probable indicator of the forthcoming 
cardiac diseases. It is the analysis of the heart rate against time axis. HRV 
analysis is a non-invasive tool for the assessment of autonomic function 
linked with autonomic nervous system. HRV predicts sympathetic, 
parasympathetic and autonomic balance and also assesses the risk factors 
such as sudden cardiac death. 
 LF – low frequency   range is associated with sympathetic activity 
and high frequency range is associated with parasympathetic activity. The 
difference in frequency helps us to differentiate the sympathetic and 
parasympathetic actions. 
By analysing HRV parameters, autonomic imbalance in diabetes 
can be prevented at an early stage which could be beneficial to prevent 
the complication of diabetes mellitus. Hence we did this study to find out 
whether the offsprings of the diabetic patients who were not diabetics 
(i.e) normal individuals when compared with offsprings of diabetics who 
had diabetes mellitus would have a gross impairment of autonomic 
function. Frequency domain measures of HRV is a sensitive, quantitative 
method to assess the sympathetic and parasympathetic system. There is 
possibility of tachycardia and decrease in beat to beat changes  if there is 
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a greater involvement of  sympathetic activity in the individual. If the 
parasympathetic influence is more in an individual then there are greater 
chances of bradycardia and consequently there is increased beat to beat 
variation. Reduced variation in heartbeat is an early predictor of 
cardiovascular disease and this can even increase the mortality rate in 
them. 
Comparison of HRV parameters (Time domain measures) between 
the control and the study group 
1. Mean RR interval and mean HR  
The mean RR interval and HR denote the balance of sympathetic 
and parasympathetic activity of ANS. The reduced heart rate and the 
prolonged RR interval denote parasympathetic overactivity and increased 
heart rate and decreased RR interval denote sympathetic dominance. 
In our study, offsprings of diabetics who were diabetics showed a 
decrease in mean RR and increase in HR and the difference was 
statistically significant compared to the control group. This denotes the 
offsprings of diabetes who were suffering from type 2 DM have 
sympathetic over activity compared to offsprings of diabetics without 
diabetes mellitus. 
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RR variability is shown in diabetic patients and they are prone to 
cardiac arrthymias and death. 
2. SDNN 
Heart rate is calculated from the RR interval of ECG. Other 
parameters like SDNN, the standard deviation of NN interval, RMSSD 
the root mean square of successive difference of interval and PNN50, the 
number of successive difference of interval which differ by more than 50 
millisecond expressed as % of the total number of ECG cycles are 
analysed. 
In our study, SDNN of our study group was decreased when 
compared to the control group.  Shemaila Saleem in her study proved that 
there was a decrease in time frequency parameters of HRV among 
diabetes.
67
 
Thurston J H, Mcdougal D B et al stated in their research paper 
that there was a decrease in SDNN among diabetic patients which had a 
negative prognostic value and was a predictor of autonomic neurapathy. 
They stated that the metabolic disturbances which occurred in diabetes 
and malnutrition of autonomic nerve may lead to diabetic neurapathy 
also.
68
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Our study showed a decreased value of SDNN in diabetic subjects 
which was similar to this study 
RMSSD 
RMSSD is a time domain parameter of HRV. European heart 
journal guidelines state RMSSD method is a preferred, better statistical 
method. RMSSD was decreased in the study group compared to the 
control group of nondiabetic offsprings. This finding was consistent with 
the study done by Claudio de Angeles and Pietro Perelli
45
. 
A Fiorentini et al had also demonstrated decrease in RMSSD in the 
study group compared to the control group without diabetic mellitus. A 
significant reduction of the total autonomic system activity indicates the 
familiarity of type2 diabetes mellitus relating it to the global reduction of 
ANS activity and dysautonomia increase if offsprings were insulin 
resistant. The full blown ANS impairment activity is seen in type 2 DM 
which was consistent with our study 
49
. 
pNN50 
pNN 50 is the NN50 count divided by the total number of all `N' 
intervals in our studies pNN50 was found to be decreased in the study 
group and it showed an increase in sympathetic and parasympathetic 
activity indicating cardiac electrical instability. Our study was consistent 
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with the study done by Claudio de Angeles et al denoting sympathovagal 
imbalance in offsprings of diabetic patients
45
. 
Analysis of Frequency Domain Measures of HRV 
 Frequency domain analysis is considered as precise tool for 
assesing autonomic function.  Frequency domain parameters like LF, HF 
and LF/HF ratio have been analysed. There is a general belief that LF 
denotes sympathetic component but there is difference of opinion 
regarding this as some others believe that it denotes both sympathetic as 
well as parasympathetic component. LF/HF ratio denotes the sympathetic 
balance. A decrease in ratio indicates increased parasympathetic tone. 
LF nu  
In our study LF nu was slightly increased in the study group and 
the difference was found to be statistically significant. LF is a quantitative  
marker of sympathetic modulation and it is an important parameter of 
HRV depicting sympathetic activity. The marginal increase in LF nu in 
the study group of offsprings of diabetics with diabetes is supporting the 
proposed statement of Perin PC et al. The hypothesis was such that vagal 
impairment in diabetic patients is due to early autonomic neuropathy.
69
 
Sympathetic activity dominates due to impairment of vagal activity 
so that sympathovagal homeostatic mechanism is maintained. 
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HF nu 
In our study HF nu was marginally decreased in the study group of 
offsprings of diabetics with diabetes compared to the control group 
without diabetes which was statistically insignificant. 
HF component determines parasympathetic activity. This finding 
was consistent with the study done by H Kudet et al who did a research 
study on HRV with 30 diabetic patients denoting suppression of 
parasympathetic activity in diabetics
70
. 
This study was similar to our study. Axonal degeneration of the 
vagal nerve fibres would be the probability of developing neuropathy 
which is a complication of DM. 
LF/HF Ratio 
LF/HF ratio is a marker of sympathovagal balance. LF/HF ratio 
was increased in the study group compared to the control and the 
difference was found to be statistically insignificant. Our observation was 
similar to the study done by H. Kudat et al in which parasympathetic 
activity was diminished in diabetics with the HF power being reduced, 
thereby LF/HF ratio was increased denoting sympathetic dominance. 
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Lipid Profile 
In our study the mean value of cholesterol, low density lipoprotein, 
high density lipoprotein showed a statistically insignificant decrease in 
the study group compared to the control group. 
Fathima Ali Hasan et al in their study found that diabetic 
atherosclerotic patients had increased levels of cholesterol, triglycerides, 
LDL and low level of HDL compared to similar such parameters in non-
diabetic atherosclerotic patients and normal controls 
71
. 
The low level of cholesterol and LDL in diabetics of the study 
group, could be due to their treatment schedule for dyslipidaemia  (i.e) 
cholesterol lowering drugs like statins. Thus the study group showed a 
discrepancy in the results compared to previous studies. Triglycerides 
were increased in the study group compared to the control group denoting 
hypertriglyceridemia in the diabetic study group which did not respond to 
the drugs like statins. 
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CORRELATION STUDIES 
We did correlations analysis of HbA1c with HRV parameters in the 
study group of offsprings of diabetics with diabetes and the results are 
discussed below. 
Correlation of HbA1c with time domain parameters of HRV 
In our study there was a negative correlation of mean RR, SDNN, 
pNN50 and RMSSD  denoting an increase in sympathetic activity in 
individual with increased HbA1c. The mean HR showed a positive 
correlation predicting parasympathetic dominance. 
Correlation of HbA1c with frequency domain parameters of HRV  
HbA1c and LF, HF, LF/HF ratio 
In our studies HbA1c is positively correlated with LF ratio denoting 
predominance of sympathetic activity. The HF and LF/HF was negatively 
correlated with HbA1c denoting suppression of parasympathetic activity 
and increased sympathetic activity. In diabetes, hyperglycemia increases 
the progression of cardiac autonomic neuropathy initiating 
sympathovagal imbalance resulting in increase in LF/HF ratio HbA1c 
reflects the status of glycemic control. 
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Finally our study revealed significant changes in time and 
frequency domain parameters of short term HRV in diabetic offsprings of 
diabetics denoting autonomic dysfunction in diabetic individuals who 
were offsprings of diabetics. 
Correlation of HRV parameter (Time domain measures) with BMI 
In our study, there was a positive correlation of mean RR interval 
denoting an increase in sympathetic activity, in individual with increased 
BMI. The negative correlation of mean HR, pNN50, RMSSD 
representing a decrease in parasympathetic activity. 
Correlation of HRV parameters (Frequency domain measures) with 
BMI 
In our studies BMI is positively correlated with LF showing 
sympathetic dominance whereas HF and LF/HF ratio is negatively 
correlated with BMI denoting parasympathetic dominance 
Correlation of HRV parameters (Time Domain Measures) with Lipid 
Profile 
 There was a positive correlation of cholesterol, triglycerides, LDL, 
HDL, with mean RR interval denoting sympathetic over activity and 
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negative correlation of mean HR, pNN50 and RMSSD denoting 
parasympathetic activity suppression. 
Correlation of HRV parameters (Frequency Domain Measures) with 
Lipid Profile 
There was a positive correlation of cholesterol triglycerides, LDL, 
HDL with LF norm and LF/HF ratio showing sympathetic dominance and 
negative correlation of HF denoting diminished parasympathetic activity 
Study Limitations 
There were a few limitations in our study: 
• The study group sample size was small and it can be increased for 
further study in future. 
• We did the short term HRV (i.e) 5 minutes recording. This can be a 
long term assessment for a period of 24 hours. Short time HRV can 
only be used for screening of patients at the initial stage. 
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CONCLUSION 
Globally, the fifth leading cause of death is diabetes mellitus.
66
 The 
rapidity with which type 2 diabetes mellitus has increased has shown 
effectively that there is a global epidemic of type 2 diabetes mellitus. 
HRV is a simple, non-invasive assessment tool in predicting 
autonomic dysfunction in diabetic patients. Even in offsprings of diabetic 
patients who did not have diabetes, autonomic modulations if any, can be 
picked up by HRV analysis. Hence we did a study in comparing the time 
and frequency domain parameters in offsprings of diabetics with diabetes 
and offsprings of diabetics without diabetes. 
Time domain measures of HRV in offsprings of diabetics with 
diabetes showed a reduced mean RR and increased HR which is 
applicable to represent significant sympathetic dominance and a 
decreased RMSSD and pNN50 implies a significant reduction in 
parasympathetic activity. 
The marginally increased LF nu indicates increased sympathetic 
activity whereas marginally decreased HF nu relates a decrease in 
parasympathetic activity. The increased LF/HF ratio is due to reduced 
parasympathetic activity or impaired sympathetic activity. These are the 
frequency domain measures measured in HRV related with our study. 
To summarise, it is well documented that diabetes mellitius cause 
an alteration in sympathovagal balance with domination of sympathetic 
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activity and suppression of parasympathetic activity. These patients are 
more prone to develop cardiovascular complication like ventricular 
tachyarrhythmias and atrial fibrillation and this can lead to silent 
myocardial infarction and death. 
In diabetic patients the important findings is comparing autonomic 
dysfunction with HbA1c level. The result showed patients with poor 
glycaemic control had autonomic impairment in respect to normal 
individuals with normal blood sugar level. 
Hence it is very essential to screen the diabetic patients and do a 
HRV analysis so that autonomic dysfunction can be picked up at an early 
stage and stringent control of diabetes mellitus with medication and life 
style modification with appropriate diet, and regular exercise, practising 
yoga can be carried out to improve parasympathetic tone reducing the 
cardiovascular morbidity and mortality. 
The offsprings of diabetics who did not have diabetes can be 
regularly screened for diabetes, appropriate BMI can be maintained with 
regular exercise so that the development of diabetes in them, even if they 
have genetic predisposition can be postponed. A more detailed study 
involving more member of diabetic patients with or without complication, 
is necessary to come to a definite conclusion to rule out the degree of 
autonomic dysfunction in them. 
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ANNEXURE I 
DATA COLLECTION TOOL 
NAME: 
AGE: 
SEX: 
OCCUPATION: 
HEIGHT: 
WEIGHT: 
TREATMENT HISTORY: 
FAMILY HISTORY: 
ARE YOU ON TREATMENT FOR ANY OTHER CHRONIC DISEASE: 
1) Hypertension  
2) Any cardiac illness 
3) Bronchial asthma 
4) hyperthyroidism 
5) Chronic use of any medications 
PERSONAL HISTORY (ALCOHOLIC/SMOKING/TOBACCO CHEWING): 
Blood Pressure: 
Duration of diabetes: 
Diabetic complication: 
           SIGNATURE OF PARTICIPANTS 
ANNEXURE II 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS (strike off 
items that are not applicable) 
I, (DR SM IMTHIAZ) am carrying out a study on the topic ”A STUDY OF 
THE HEART RATE VARIABLITY IN OFFSPRINGS OF TYPE 2 
DIABETES MELLITUS” as part of my / our research project being carried out 
under the aegis of the Department of: PHYSIOLOGY  
(Applicable to students only): My / our research guide is: G.V.LATHA DEVI 
The justification for this study is:  
By doing this study we try to evaluate Heart Rate Variablity in offspring's of 
type 2 diabetes mellitus patients patients is not yet been studied in detail so far. 
Hence this study would be helpful in rectifying that lacuna. Any insights 
gained can ultimately be used to improve health care delivery for this group. 
The objectives of this study are:  
Primary objective: 
The aim of the study is to analyze the Heart rate variability in offspring's of 
type 2 diabetes with diabetes mellitus. 
Comparison with Non Diabetic offspring's of Type 2 Diabetes Mellitus patients 
Sample size:  
30 Test group with diabetes mellitus. 
     30 control group without diabetes mellitus.  
Study volunteers / participants are (specify population group & age group): 30 
TO 70 YEARS MALES AND FEMALES.. 
Location: COIMBATORE 
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will 
be carrying out:  
Initial interview (specify approximate duration 60 minutes.  
Data collected will be stored for a period of FIVE years. We will / will not use 
the data as part of another study. 
Health education sessions: Number of sessions: ONE SESSION Approximate 
duration of each session:  
10 minutes.  
 
Clinical examination (Specify details and purpose):  
Blood sample collection: Specify quantity of blood being drawn: 
___________ml.  
No. of times it will be collected: _______________.  
Whether blood sample collection is part of routine procedure or for research 
(study) purpose:  
1. Routine procedure 2. Research purpose  
Specify purpose, discomfort likely to be felt and side effects, if any: 
_______________________________ 
Whether blood sample collected will be stored after study period: Yes / No, 
it will be destroyed 
Whether blood sample collected will be sold: Yes / No  
Whether blood sample collected will be shared with persons from another 
institution: Yes / No 
Medication given, if any, duration, side effects, purpose, benefits:  
Whether medication given is part of routine procedure: Yes / No (If not, state 
reasons for giving this medication) 
Whether alternatives are available for medication given: Yes / No (If not, state 
reasons for giving this particular medication) 
Final interview (specify approximate duration):_________ mts. If photograph 
is taken, purpose:  
Benefits from this study:  
Risks involved by participating in this study: 
How the results will be used:  
If you are uncomfortable in answering any of our questions during the course 
of the interview / biological sample collection, you have the right to withdraw 
from the interview / study at anytime. You have the freedom to withdraw from 
the study at any point of time. Kindly be assured that your refusal to participate 
or withdrawal at any stage, if you so decide, will not result in any form of 
compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a 
patient. You will NOT be paid any remuneration for the time you spend with us 
for this interview / study. The information provided by you will be kept in strict 
confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be 
used for approved research purposes only. You will be informed about any 
significant new findings - including adverse events, if any, – whether directly 
related to you or to other participants of this study, developed during the course 
of this research which may relate to your willingness to continue participation. 
Consent: The above information regarding the study, has been read by me/ read 
to me, and has been explained to me by the investigator/s. Having understood 
the same, I hereby give my consent to them to interview me. I am affixing my 
signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements).  
Signature / Left thumb impression of the Study Volunteer / Legal 
Representative:  
Signature of the Interviewer with date:     
 Witness: 
Contact number of PI: 
Contact number of Ethics Committee Office: 0422 4345818  
 
 
 
 
 
 
 
 
ANNEXURE III 
xg]g[jy] gotk]] [ ] ]] [ ] ]] [ ] ] 
 lhf]lh] rh.K.,k]jpah!] Mfpa ehd] PSG kUj]Jtf] fy]Y}hpapd] 
clypa']fpay] Jiwapd] fPH]/ ilg] 2 "ePhpHpt[ neha] cs]sth]fspd] [ ] ] ] ][ ] ] ] ][ ] ] ] ]
re]jjpapdhpd] ,Uja Jog]g[ ntWghl]il gof]Fk] Ma]t[] ] ] [ ] ] ] ] [] ] ] [ ] ] ] ] [] ] ] [ ] ] ] ] [" vd]w jiyg]gpy] 
Ma]t[ nkw]bfhs]s cs]nsd].  
vd] Ma]t[ tHpfhl]o: lhf]lh] yjh njtp] ]] ]] ]  
Ma]t[ nkw]bfhs]tjw]fhd mog]gil] [ ] ] ] ]] [ ] ] ] ]] [ ] ] ] ] : 
 ilg] 2 ePhpHpt[ nehia gw]wpa Ma]t[fs] ,Ue]jhYk] mth]fspd] 
re]jjpapdhpd] ,Uja Jog]gpd] ntWghl]il gw]wpa Ma]t[fs] rpy kl]Lnk 
cs]sd. mjdhy] ,e]j Ma]it nkw]bfhs]fpnwd]. 
Ma]tpd] nehf]fk]] ] ] ]] ] ] ]] ] ] ] : 
 ilg] 2 ePhpHpt[ neha] cs]sth]fspd] re]jjpapdhpd] ,Uja Jog]ig 
ntWghl]il gof]Fk] Ma]t[. 
Ma]tpy] g']F bgWk] egh]fspd] vz]zpf]if: 60 
Ma]t[ nkw]bfhs]Sk] ,lk] : clypa']fpay] kw]Wk] KG cly] ghpnrhjid 
ikag] gphpt[/ gp.v!].$p. kUj]Jtkid/ nfhak]g[j]J}h]. 
Ma]tpd] gyiffs] : ePhpHpt[ neha] cs]sth]fspd] re]jjpapdhpd] ,Uja 
Jog]gpd] ntWghl]il fz]lwpa[k] Ma]t[. 
 Ma]tpdhy] Vw]gLk] mbrsfhpa']fs]/ gf]f tpist[fs] vJt[k] 
,y]iy. ,e]j Ma]tpy] fpilf]Fk] jfty]fs] 5 tUl']fs] ghJfhf]fg]gLk]. 
,it ntbwe]j Ma]tpw]Fk] gad]gLj]jg]glkhl]lhJ. ve]j epiyapYk] 
c']fisg] gw]wpa jfty]fs] ahUf]Fk] bjhptpf]fg]glkhl]lhJ. mit 
,ufrpakhf itf]fg]gLk]. 
 ,e]j Ma]tpy] g']nfw]f xg]g[f]bfhs]Stjhy] ve]j tpjkhd gyDk] 
c']fSf]Ff] fpilf]fhJ. ve]j neuj]jpy] ntz]LkhdhYk] Ma]tpypUe]J 
tpyfpf]bfhs]Sk] chpik c']fSf]F cz]L. 
Ma]tpypUe]J tpyfpf] bfhs]tjhy] c']fSf]F mspf]fg]gLk] rpfpr]irapy] 
ve]jtpj khw]wKk] ,Uf]fhJ. 
,e]j Muha]r]rpf]fhf c']fsplk] rpy nfs]tpfs] nfl]fg]gLk]/ rpy ,uj]j 
khjphpfs] my]yJ jpR khjphpfs] vLf]fg]gLk]. 
nkYk]/ ,e]j Ma]tpy] g']F bfhs]tJ c']fs] brhe]j tpUg]gk]. ,jpy] 
ve]jtpjf] fl]lhaKk] ,y]iy. eP']fs] tpUg]gg]gl]lhy]/ ,e]j Ma]tpd] 
Kot[fs] c']fSf]Fj] bjhpag]gLj]jg]gLk]. 
Ma]thshpd] ifbahg]gk] : 
njjp: 
Ma]t[f]Fl]gLgthpd] xg]g[jy] : 
ehd] ,e]j Muha]r]rpapd] nehf]fk] kw]Wk] mjd] gad]ghl]oidg] gw]wp 
bjspthft[k]/ tpsf]fkhft[k] bjhpag]gLj]jg]gl]Ls]nsd]. ,e]j Muha]r]rpapy] 
g']F bfhs]st[k]/ ,e]j Muha]r]rpapd] kUj]Jt hPjpahd Fwpg]g[fis tUk] 
fhyj]jpYk] cgnahfg]gLj]jpf] bfhs]st[k] KGkdJld] rk]kjpf]fpnwd]./ 
Ma]t[f]Fl]gLgthpd] bgah]/ Kfthp: 
ifbahg]gk] : 
njjp: 
 
Ma]thshpd] bjhiyngrp vz] : 
kdpj bewpKiwf] FG mYtyfj]jpd] bjhiyngrp vz]. 0422 2570170 Extn : 5818 
 
 
 
 
ANNEXURE IV – Offsprings of type 2 diabetes mellitus who were not diabetics (control group) 
  
 S.NO AGE SEX BMI  LF nu HF nu 
LF/HF 
Ratio  
SDNN 
Mean R-
R 
Mean H-
R 
pNN50 of R-R Int. RMSSD HbA1c 
Glucosefasting 
(Plasma) 
PP.B.S Cholesterol  Triglycerides  HDL  LDL  
1 
 
58 F 29 31.734 68.266 0.4649 63.29 885.75 67.3 1.63934426229508 24.0068483379907 5.6% (3.8-6.3) 78 86 240 100 59 181 
2 49 M 33 48.707 51.293 0.9496 67.98 964.31 61.8 1.7910447761194 24.7502872226606 5.4% (3.8-6.3) 88 112 159 96 30 126 
3 67 M 30.8 56.784 43.216 1.314 83.81 1013.15 58.89 5.95611285266458 33.0572212113153 5% (3.8-6.3) 103 101 158 77 56 104 
4 39 M 20.5 60.275 39.725 1.5173 54.17 773.88 77.02 0.467289719626168 14.816204180666 5.8% (3.8-6.3) 102 128 217 215 31 168 
5 45 M 24.2 47.923 52.077 0.9202 63.41 868.72 68.61 0.804289544235925 18.276402318849 6% (3.8-6.3) 97 149 202 141 29 160 
6 40 F 30 45.131 54.869 0.8225 85.72 960.77 62.23 13.0311614730878 46.5217446714193 5.7% (3.8-6.3) 100 114 174 78 53 126 
7 44 M 29 31.904 68.096 0.4685 41.02 598.15 99.67 0 10.2595468994993 6% (3.8-6.3) 123 154 208 222 39 157 
8 41 F 29.7 17.259 82.741 0.2086 59.05 793.71 75.13 1.47783251231527 21.3102315575996 5.2% (3.8-6.3) 96 136 158 110 41 107 
9 51 M 35.7 24.465 75.535 0.3239 44.24 645.32 92.29 0 13.6992453335636 5.4% (3.8-6.3) 88 115 159 113 46 108 
10 26 M 29.3 60.474 39.526 1.53 44.05 609.11 97.86 0 12.5206666126142 5.2% (3.8-6.3) 99 140 198 133 36 161 
11 28 F 17.8 37.062 62.938 0.5889 67.69 834.6 71.5 3.37349397590361 23.1543862770045 5.2% (3.8-6.3) 104 130 170 57 64 113 
12 29 F 19.7 45.396 54.604 0.8314 55.74 793.14 75.13 1.48514851485149 20.8927902603631 5.6% (3.8-6.3) 84 107 153 99 37 112 
13 40 M 25.1 59.271 40.729 1.4553 65.78 913.08 65.28 3.38028169014084 24.2220675233674 5.9% (3.8-6.3) 90 128 117 130 29 71 
14 25 M 23.7 37.33 62.67 0.5957 47.28 629.52 94.71 0.382409177820268 15.281270934687 5.5% (3.8-6.3) 84 98 152 66 39 116 
15 41 M 22.9 79.196 20.804 3.8068 217.19 1226.03 46.48 22.568093385214 92.6841705403355 5.4% (3.8-6.3) 94 130 197 136 42 145 
16 38 M 24.2 65.301 34.699 1.8819 74.89 1062.89 56.04 7.21311475409836 33.3058150530783 5.1% (3.8-6.3) 93 104 175 83 66 110 
17 58 M 26.7 50.784 49.216 1.0319 66.4 768.1 77.81 3.5377358490566 25.990905417952 5.8% (3.8-6.3) 108 127 202 87 61 146 
18 28 F * 46.245 53.755 0.8603 49.42 678.68 87.78 1.57068062827225 15.0381874444622 5.4% (3.8-6.3) 91 103 183 55 66 122 
19 36 F 24.9 43.11 56.89 0.7578 52.88 743.13 80.17 0.544959128065395 14.3330791691787 5.1% (3.8-6.3) 99 161 201 91 46 158 
20 41 M 26.5 42.986 57.014 0.754 63.56 798.86 74.7 1.68269230769231 22.6756596854132 5.8% (3.8-6.3) 110 122 214 322 36 163 
21 42 M 17.8 23.542 76.458 0.3079 62.41 819.4 72.77 3.54430379746835 28.1602106158483 5.7% (3.8-6.3) 92 136 230 124 40 183 
22 38 M 33.3 57.003 42.997 1.3257 51.59 705.75 84.44 0.218818380743982 15.017460597818 5.7% (3.8-6.3) 106 140 304 168 48 252 
23 42 M 27 48.229 51.771 0.9316 73.03 978.76 60.91 5.72289156626506 32.4120935245862 5.6% (3.8-6.3) 102 129 173 123 38 139 
24 32 M 25.2 33.749 66.251 0.5094 51.16 735.85 80.97 0 13.8924439894498   87 157 179 104 28 146 
25 59 M 24.9 55.219 44.781 1.2331 103.57 910.12 66.08 8.4985835694051 39.853781045672 5.4% (3.8-6.3) 94 91 185 82 34 150 
26 56 F 25 32.639 67.361 0.4845 45.5 677.91 87.79 0 14.2075320958275 6.5% (3.8-6.3) 109 136 217 135 57 156 
27 38 M 31.6 59.653 40.347 1.4785 60.77 785.38 75.99 1.48514851485149 21.8845881270541 5.8% (3.8-6.3) 101 131 203 77 49 150 
28 35 M 25 44.297 55.703 0.7952 98.79 1018.21 58.79 16.5625 64.3331357163412 5.7% (3.8-6.3) 119 132 186 94 45 143 
29 42 M 28.7 36.032 63.968 0.5633 44.75 634.2 93.93 0 10.8068227826266 5.6% (3.8-6.3) 98 135 183 137 35 140 
30 31 M 23.2 32.315 67.685 0.4774 73.15 943.04 63.26 3.79008746355685 25.7569044851079 5.1% (3.8-6.3) 98 130 153 58 53 100 
ANNEXURE V – Offsprings of type 2 diabetes mellitus who were diabetics (study group) 
 
 
S.NO AGE SEX BMI  LF nu HF nu 
LF/HF 
Ratio  
SDNN 
Mean R-
R 
Mean H-
R 
pNN50 of R-R Int. RMSSD HbA1c 
Glucosefasting 
(Plasma) 
PP.B.S Cholesterol  Triglycerides  HDL  LDL  
1 
 
58 F 29 31.734 68.266 0.4649 63.29 885.75 67.3 1.63934426229508 24.0068483379907 5.6% (3.8-6.3) 78 86 240 100 59 181 
2 49 M 33 48.707 51.293 0.9496 67.98 964.31 61.8 1.7910447761194 24.7502872226606 5.4% (3.8-6.3) 88 112 159 96 30 126 
3 67 M 30.8 56.784 43.216 1.314 83.81 1013.15 58.89 5.95611285266458 33.0572212113153 5% (3.8-6.3) 103 101 158 77 56 104 
4 39 M 20.5 60.275 39.725 1.5173 54.17 773.88 77.02 0.467289719626168 14.816204180666 5.8% (3.8-6.3) 102 128 217 215 31 168 
5 45 M 24.2 47.923 52.077 0.9202 63.41 868.72 68.61 0.804289544235925 18.276402318849 6% (3.8-6.3) 97 149 202 141 29 160 
6 40 F 30 45.131 54.869 0.8225 85.72 960.77 62.23 13.0311614730878 46.5217446714193 5.7% (3.8-6.3) 100 114 174 78 53 126 
7 44 M 29 31.904 68.096 0.4685 41.02 598.15 99.67 0 10.2595468994993 6% (3.8-6.3) 123 154 208 222 39 157 
8 41 F 29.7 17.259 82.741 0.2086 59.05 793.71 75.13 1.47783251231527 21.3102315575996 5.2% (3.8-6.3) 96 136 158 110 41 107 
9 51 M 35.7 24.465 75.535 0.3239 44.24 645.32 92.29 0 13.6992453335636 5.4% (3.8-6.3) 88 115 159 113 46 108 
10 26 M 29.3 60.474 39.526 1.53 44.05 609.11 97.86 0 12.5206666126142 5.2% (3.8-6.3) 99 140 198 133 36 161 
11 28 F 17.8 37.062 62.938 0.5889 67.69 834.6 71.5 3.37349397590361 23.1543862770045 5.2% (3.8-6.3) 104 130 170 57 64 113 
12 29 F 19.7 45.396 54.604 0.8314 55.74 793.14 75.13 1.48514851485149 20.8927902603631 5.6% (3.8-6.3) 84 107 153 99 37 112 
13 40 M 25.1 59.271 40.729 1.4553 65.78 913.08 65.28 3.38028169014084 24.2220675233674 5.9% (3.8-6.3) 90 128 117 130 29 71 
14 25 M 23.7 37.33 62.67 0.5957 47.28 629.52 94.71 0.382409177820268 15.281270934687 5.5% (3.8-6.3) 84 98 152 66 39 116 
15 41 M 22.9 79.196 20.804 3.8068 217.19 1226.03 46.48 22.568093385214 92.6841705403355 5.4% (3.8-6.3) 94 130 197 136 42 145 
16 38 M 24.2 65.301 34.699 1.8819 74.89 1062.89 56.04 7.21311475409836 33.3058150530783 5.1% (3.8-6.3) 93 104 175 83 66 110 
17 58 M 26.7 50.784 49.216 1.0319 66.4 768.1 77.81 3.5377358490566 25.990905417952 5.8% (3.8-6.3) 108 127 202 87 61 146 
18 28 F * 46.245 53.755 0.8603 49.42 678.68 87.78 1.57068062827225 15.0381874444622 5.4% (3.8-6.3) 91 103 183 55 66 122 
19 36 F 24.9 43.11 56.89 0.7578 52.88 743.13 80.17 0.544959128065395 14.3330791691787 5.1% (3.8-6.3) 99 161 201 91 46 158 
20 41 M 26.5 42.986 57.014 0.754 63.56 798.86 74.7 1.68269230769231 22.6756596854132 5.8% (3.8-6.3) 110 122 214 322 36 163 
21 42 M 17.8 23.542 76.458 0.3079 62.41 819.4 72.77 3.54430379746835 28.1602106158483 5.7% (3.8-6.3) 92 136 230 124 40 183 
22 38 M 33.3 57.003 42.997 1.3257 51.59 705.75 84.44 0.218818380743982 15.017460597818 5.7% (3.8-6.3) 106 140 304 168 48 252 
23 42 M 27 48.229 51.771 0.9316 73.03 978.76 60.91 5.72289156626506 32.4120935245862 5.6% (3.8-6.3) 102 129 173 123 38 139 
24 32 M 25.2 33.749 66.251 0.5094 51.16 735.85 80.97 0 13.8924439894498 5.2% (3.8-6.3) 87 157 179 104 28 146 
25 59 M 24.9 55.219 44.781 1.2331 103.57 910.12 66.08 8.4985835694051 39.853781045672 5.4% (3.8-6.3) 94 91 185 82 34 150 
26 56 F 25 32.639 67.361 0.4845 45.5 677.91 87.79 0 14.2075320958275 6.5% (3.8-6.3) 109 136 217 135 57 156 
27 38 M 31.6 59.653 40.347 1.4785 60.77 785.38 75.99 1.48514851485149 21.8845881270541 5.8% (3.8-6.3) 101 131 203 77 49 150 
28 35 M 25 44.297 55.703 0.7952 98.79 1018.21 58.79 16.5625 64.3331357163412 5.7% (3.8-6.3) 119 132 186 94 45 143 
29 42 M 28.7 36.032 63.968 0.5633 44.75 634.2 93.93 0 10.8068227826266 5.6% (3.8-6.3) 98 135 183 137 35 140 
30 31 M 23.2 32.315 67.685 0.4774 73.15 943.04 63.26 3.79008746355685 25.7569044851079 5.1% (3.8-6.3) 98 130 153 58 53 100 
